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Abstract
Background: Significant concerns are associated with the use of broad-spectrum antibacterial agents,
including collateral eradication of beneficial bacteria from the human microbiome, the onset of
antibacterial-associated infections, and continued emergence of antibacterial drug resistance. As such, a
critical need for novel and selective antibacterial targets exists. The investigation of two such targets,
each pertaining to the highly concerning infections caused by streptococcal species and Clostridioides
difficile, are presented herein. Bacterial topoisomerase I represents a potentially promising narrowspectrum target as studies have arisen demonstrating its essentiality in bacterial species lacking the only
other type IA topoisomerase (topoisomerase III). Additionally, recent studies demonstrating the
essentiality of the fabK gene expressing enoyl-ACP reductase II (FabK) in C. difficile indicate its significant
potential as a narrow-spectrum target. Presented here are data characterizing and validating both the
TopoI and FabK enzymes as novel antibacterial targets via the implementation of an array of drug
discovery techniques, including structural studies, biochemical assay development and application, and
inhibitor screening and testing. Methods: An assortment of drug discovery techniques were employed for
the targeting of SmTopoI and CdFabK, including different protein expression and purification techniques;
X-ray crystallography; various biophysical and biochemical techniques for target characterization,
validation, and drug screening; and different lead development and optimization studies. Results: The
respective genes for SmTopoI and CdFabK have been cloned, and the expression and purification of
various constructs of each target have been carried out and optimized for further analysis. The crystal
structure of SmTopoI_N65 has been determined to 2.06 Å and diffracting CdFabK crystals (3.5 Å) have
been attained. A high-throughput plate-based biochemical fluorescence kinetic assay has been optimized
for screening against the CdFabK enzyme. Furthermore, activity and modality of inhibition assessment of
small-molecule inhibitors of the CdFabK enzyme have been conducted, including phenylimidazole and
benzothiazole compounds. Phenylimidazole analogues have been found to display micromolar inhibitory
activity against CdFabK, and a benzothiazole analogue has been found to display nanomolar inhibitory
activity against the target. Conclusions: The SmTopoI and CdFabK enzymes present potentially novel,
narrow- spectrum antibacterial drug targets, and substantial progress has been made toward the rational
targeting of these two enzymes. Of particular note, the first structure of a Topo I fragment from a grampositive organism, S. mutans, has been determined. Enzymology and inhibitor studies have been
conducted supporting the druggability of CdFabK and indicating the potential for selective inhibition of
CdFabK.
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ABSTRACT
Background: Significant concerns are associated with the use of broad-spectrum
antibacterial agents, including collateral eradication of beneficial bacteria from the
human microbiome, the onset of antibacterial-associated infections, and continued
emergence of antibacterial drug resistance. As such, a critical need for novel and
selective antibacterial targets exists. The investigation of two such targets, each
pertaining to the highly concerning infections caused by streptococcal species and
Clostridioides difficile, are presented herein. Bacterial topoisomerase I represents a
potentially promising narrow-spectrum target as studies have arisen demonstrating its
essentiality in bacterial species lacking the only other type IA topoisomerase
(topoisomerase III). Additionally, recent studies demonstrating the essentiality of the
fabK gene expressing enoyl-ACP reductase II (FabK) in C. difficile indicate its
significant potential as a narrow-spectrum target. Presented here are data characterizing
and validating both the TopoI and FabK enzymes as novel antibacterial targets via the
implementation of an array of drug discovery techniques, including structural studies,
biochemical assay development and application, and inhibitor screening and testing.
Methods: An assortment of drug discovery techniques were employed for the targeting
of SmTopoI and CdFabK, including different protein expression and purification
techniques; X-ray crystallography; various biophysical and biochemical techniques for
target characterization, validation, and drug screening; and different lead development
and optimization studies.
Results: The respective genes for SmTopoI and CdFabK have been cloned, and the
expression and purification of various constructs of each target have been carried out and
optimized for further analysis. The crystal structure of SmTopoI_N65 has been
determined to 2.06 Å and diffracting CdFabK crystals (3.5 Å) have been attained. A
high-throughput plate-based biochemical fluorescence kinetic assay has been optimized
for screening against the CdFabK enzyme. Furthermore, activity and modality of
inhibition assessment of small-molecule inhibitors of the CdFabK enzyme have been
conducted, including phenylimidazole and benzothiazole compounds. Phenylimidazole
analogues have been found to display micromolar inhibitory activity against CdFabK,
and a benzothiazole analogue has been found to display nanomolar inhibitory activity
against the target.
Conclusions: The SmTopoI and CdFabK enzymes present potentially novel, narrowspectrum antibacterial drug targets, and substantial progress has been made toward the
rational targeting of these two enzymes. Of particular note, the first structure of a Topo I
fragment from a gram-positive organism, S. mutans, has been determined. Enzymology
and inhibitor studies have been conducted supporting the druggability of CdFabK and
indicating the potential for selective inhibition of CdFabK.
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CHAPTER 1.

INTRODUCTION1

Overview
The current threat of antibacterial resistance looms large across the entire globe.
Only a century ago, the threat posed by bacterial infections seemed all but defeated. As
initial antibacterial breakthroughs were made, humanity’s victory over such infections
was generally regarded as a near guarantee. As resistance mechanisms surfaced, however,
pathogenic bacterial infections crept their way back into the healthcare arena, regaining
an insidious foothold that, in retrospect, now appears to have been underestimated.
Resistances continued to evolve, outpacing novel and effective antibacterial drug
development and cutting into the hard-won gains humanity had made. Eventually, easily
treated infections again became dire and the world is once more on alert, demonstrating
the significant need for a modern and concerted effort to develop novel antibacterial
agents. A compelling modern argument is being made that such an effort should include,
at least in part, an investigation of narrow-spectrum targets for the development of these
much needed novel antibacterial agents. A brief survey of the historic eras, modern
efforts, and possible future of antibacterial drug discovery may act as a road map for such
a case. Furthermore, a discussion of the requirements such narrow spectrum
investigations entail helps to accurately present the accompanying benefits and costs.
Antibacterial Drug Discovery Eras: Past, Present, and Future
The Golden Era
Before the advent of antibacterial drugs, any insult small or large that introduced
the risk of infection was potentially fatal. From a sliver to surgery to simply being in
close proximity to a person suffering from a communicable disease, the ever-looming
threat of infectious disease was everywhere. However, in the early 1900s, an
unprecedented breakthrough occurred. In 1928, Alexander Fleming made his famously
“serendipitous” discovery of penicillin, and the “golden era” of antibacterial discovery
was born (Figure 1-1).1 During this era, phenotypic whole-cell natural product screening
predominated, bringing with it a prosperity in antibacterial drug discovery research yet to
be rivaled. The majority of antibacterial agents arose from this era, including the
penicillins, sulfonamides, vancomycin, streptomycin, chloramphenicol, tetracycline, and
erythromycin. In fact, many of these antibiotics, or their derivatives, are still in use and
relied upon today.

1

Adapted from final submission by permission of The Royal Society of Chemistry. Jones, J. A., Virga, K.
G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational Design and Optimization of
Antibacterial Agents. Medchemcomm 7, 1694-1715, https://doi.org/10.1039/C6MD00232C (2016).1
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Figure 1-1.

Antibacterial eras and recent advances.

Long past the historical “golden era” of antibacterial drug discovery, the modern
“resistance era” is being countered by new legislation and advances in the rational design
of antibacterial agents.
Reprinted from final submission by permission of The Royal Society of Chemistry.
Jones, J. A., Virga, K. G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational
Design and Optimization of Antibacterial Agents. Medchemcomm 7, 1694-1715,
https://doi.org/10.1039/C6MD00232C (2016).1
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The Medicinal Chemistry Era
An effective follow-up to this preeminent era occurred in the mid- to latetwentieth century in the form of the formidable “medicinal chemistry era.” Born out of
the golden era, the medicinal chemistry era forsook the phenotypic screening modalities
that preceded it and instead shifted researchers’ focus toward an elegant combination of
synthetic modifications of previously discovered compounds, high-throughput screening,
and prototypical library design.2 Antibacterial agents discovered or developed during this
era include ampicillin, methicillin, the cephalosporins, and the quinolones. While early
hope and expectations at the time were that this era would usher in a veritable end to the
long reign of bacterial infections, history would more realistically highlight it as an
incognizant precursor to the modern “resistance era”—an age marked by the menace of
expanding bacterial resistance coupled with the unfavorable reality of an inversely
diminishing antibacterial pipeline.3
The Resistance Era
In stark comparison to the gains made against bacterial infections during the
historical golden and medicinal chemistry eras, the contemporary resistance era is
overshadowed by a resurgence of infections for which modern antibacterials are less or
altogether ineffective, such as the “ESKAPE” pathogens (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas
aeruginosa, and Enterobacteriaceae species). Moreover, the current drug discovery
climate is noticeably less fruitful than that of its forerunners, due in part to the fact that it
is geared around more arduous and time-consuming rational drug design modalities that
highlight target-based high throughput screening (HTS) campaigns while implementing
comparatively exhaustive and limited tools like combinatorial libraries.4 The few
antibacterial agents developed during this era include linezolid and daptomycin. Apart
from relatively slower process inherent to rational drug design and discovery, additional
issues are associated with contemporary efforts that were, for the most part, innately
avoided in the past by the very nature of the phenotypic whole-cell screening methods
used in the golden era include difficulties with inadequate cell penetration, drug efflux,
and in vivo instability, to name a few. Overall, the relatively reduced output of the
modern drug discovery era combined with the accelerating occurrence of antibacterial
drug resistance and the rapid rate at which infections spread with modern travel has
merged to form an alarming modern public health concern with an even more concerning
prognosis of the future.
The Post-Antibiotic Era
Looking ahead on the antibacterial timeline, the next major antibacterial drug
discovery era is commonly forecasted as the “post-antibiotic era,” which foretells the
existence of a bleak period reminiscent of the time before the existence of antibacterial
agents—a future in which human deaths attributed to resistant microorganisms rises from
the current 700,000 per year to an excess of 10 million per year.2 The United Nations
(UN) World Health Organization (WHO) Ad hoc Interagency Coordination Group on
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Antimicrobial Resistance (IACG) reported this year (2019) that by 2050, drug-resistant
microbial diseases could cause economic damage on par to the 2008-2009 global
financial crisis, and that by 2030, up to 24 million people could be forced into extreme
poverty due simply to the effects of antimicrobial resistance.5 In order to adequately
combat this threat, a multi-faceted approach has commenced. Both public and private
entities across the globe have risen to meet the challenge of antimicrobial resistance in an
effort to avert the post-antibiotic era, including new legislative and research efforts.
Public and Private Responses to the Threat of Antimicrobial Resistance
Within the last several years of the “resistance era,” the United States has
launched several initiatives aimed at curbing the threat of infectious diseases including
legislation like the Generating Antibiotics Incentives Now Act (GAIN Act) aimed at fasttracking the development and approval of Qualified Infectious Disease Products (QIDPs).
Likewise, Europe has recently implemented its own similar responses, such as the
Innovative Medicines Initiative (IMI) ENABLE project under the “New Drugs 4 Bad
Bugs” (ND4BB) program aimed specifically at battling Gram-negative bacteria. The
WHO has also led multiple initiatives aimed at addressing antibacterial awareness,
including the launch of World Antibiotic Awareness Week, the Global Antimicrobial
Resistance Surveillance System (GLASS), the Global Antibiotic Research and
Development Partnership (GARDP), as well as the formation of the aforementioned
IACG. However, while momentum has increased, these governmental responses did not
manifest themselves spontaneously. In large part, they were the result of long-fought
battles by private citizens and associations working diligently to assess, interpret, and
raise the alarm regarding the overall problem—parts of an overall war still being fought.
Appropriately combatting the modern threat of microbial disease centers around
countering antibacterial resistance. Therefore, it is arguable that the individuals best
suited to assess the threat are infectious disease-focused healthcare professionals
themselves. Indeed, an early leader in this fight, the Infectious Disease Society of
America (IDSA) has gone to great lengths to increase public awareness of the looming
problem. As early as 2002, IDSA publicly conveyed worry for the lack of noteworthy
research and development (R&D) aimed at combatting multidrug resistant (MDR)
microbial infections.6 By 2004, IDSA had issued a clarion call to government agencies
for the enactment of formal regulatory and funding initiatives to aid in the fight against
the forthcoming antibacterial resistance crisis.7 Moreover, in 2010, IDSA introduced its
“10 x ‘20 Initiative” calling for R&D sufficient to bring 10 novel and effective systemic
antibacterial agents by the year 2020.8 By 2013, an update by the IDSA communicated
some advancement had been made, but that it still appeared inadequate to properly
confront the growing problem of resistance.9
That same year, the Centers for Disease Control and Prevention (CDC) appeared
to take the regulatory lead when it released its report titled “Antibiotic resistance threats
in the United States, 2013.”10 In the report, the CDC called out four “core actions” to
prevent antibiotic resistance, which included preventing the spread of infections and,
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therefore, the spread of resistance; tracking antibiotic resistant infections; improving
antibiotic prescribing via effective stewardship; and lastly, developing new diagnostic
tests and new drugs. Because the natural evolution of bacteria includes antibiotic
resistance, the CDC notes, the threat can be slowed with adequate measures, but never
completely avoided or suspended entirely. This concept has been showcased recently by
the existence and conservation of various elements of bacterial resistomes from isolated
cave bacteria previously unexposed to modern antibacterial drugs.11 Because of this
sobering fact, it is expected that a perpetual need for novel antibacterial drugs will always
exist.
Recent Advances in Antibacterial Drug Discovery, the Modern Era
Attempts to address the modern challenge of antibacterial drug discovery have
taken place via several different avenues. Since the 1980s, FDA approvals of new
antibacterial agents steadily declined from sixteen approvals between 1983 and 1987 to
only two approvals between 2011 and 2012, then rebounded between 2013 and 2017,
increasing to seven approvals during that period.6 First glance suggests that private and
public initiatives have begun to have a positive effect, resulting in a recent upswing in
antibacterial drug discovery efforts. However, with the exception of an extremely small
number of antibacterial agents possessing a novel mechanism of action (MOA), modern
research efforts have primarily focused on the optimization of known antibacterial agents
emphasizing rational design strategies geared around classic, conventional targets 1,6
(Table 1-1). For the most part, the substantial bulk of these targets are well validated and
have a long history of practical exploitation.4 In general, these modern antibacterial
efforts have revolved around improving or regaining overall spectra of activity of the
agents, as well as improving physicochemical properties, pharmacokinetics, adverse
effects, off-site activities, and so on. In these efforts, modern antibacterial researchers
have recently begun to “re-discover” natural products chemistry, complementing their
endeavors with contemporary approaches like rational semi-synthetic modifications.12,13
Recent advances in the rational design and optimization of antibacterial agents
include the development of various agents across multiple drug classes. Developmental
status of these novel agents range from early-stage clinical trials to recent approval by the
U.S. Food and Drug Administration (FDA) while, unfortunately, some hopeful products
have recently been withdrawn altogether.1 A brief summary of recently developed (within
the last decade), mostly small molecule antibacterial agents is as follows:
Advanced generation cephalosporins
Recent advances in the chemistry of the β-lactam antibiotics have resulted in the
approval and late-stage development of several advanced (or 5th) generation
cephalosporins that boast enhanced spectra of activity (SOA), including activity against
some Extended-Spectrum ß-Lactamase (ESBL) producers, methicillin-resistant
Staphylococcus aureus (MRSA), and Pseudomonas aeruginosa (PA). There are currently
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Table 1-1.

Overview of antibacterial agents in clinical trials or recently approved.

Class
Advanced Generation Cephalosporins
Cefiderocol
Ceftaroline
Ceftabiprole
Ceftolozane
Next-Generation Beta-Lactamase Inhibitors
AI101
Avibactam
ETX2514
Nacubactam
Relebactam
Vaborbactam
VNRX-5133
Zidebactam
Next-Generation Oxazolidinones
Contezolid (MRX-I)
Radezolid
Tedizolid
Next-Generation Bacterial Topoisomerase Inhibitors
Avarofloxacin
Delafloxacin
Finafloxacin
Gepotidacin
Nemonoxacin
Zabofloxacin
Zoliflodacin
Next-Generation Tetracyclines
Eravacycline approved 2018
Omadacycline approved 2018
TP6076 Phase 1
Next-Generation Macrolides
Solithromycin
Nafithromycin
Cethromycin

Novel
Agents*
4

Novel
MOAs
1
No
No
YES
No
0
No
No
No
No
No
No
No
No
0
No
No
No
2
No
No
No
YES
No
No
YES
0
No
No
No
0
No
No
No

8

3

7

3

3

6

Novel
Targets
0
No
No
No
No
0
No
No
No
No
No
No
No
No
0
No
No
No
0
No
No
No
No
No
No
No
0
No
No
No
0
No
No
No

Early Stage
(Phase 1)
0

Status
Late Stages
(Phase 2 to 3)
2
Phase 3

Recently
Approved
2
2010

Phase 3
4

2
Phase 3

2014
2
2015

Phase 1
Phase 1
Phase 3
2017
Phase 1
Phase 1
0

0

2
Phase 2
Phase 2
5
Phase 2

1
2014
2
2017
2014

1
Phase 1
0

Phase 2
Phase 3
Phase 3
Phase 2
0

3
Phase 3
Phase 2
Phase 3

2
2018
2018
0

Table 1-1.

Continued.

Class
Next-Generation Aminoglycosides
Plazomicin
Novel Bacterial Folate Synthesis Inhibitors
Iclaprim
Novel Inhibitors of the Bacterial FAS-II Pathway
Afabicin desphosphono (Debio-1452)
CG400549
Novel Lipoglycopeptides
Dalbavancin
Oritavancin
Novel Penems
Sulopenem Phase 3
Tebipenem (SPR994) Phase 1
Novel Monobactams
LYS228
Other Novel Agents
Fosfomycin disodium (epoxide, cell wall synthesis inhibitor)
Fusidic acid (fusidane, protein synthesis inhibitor)
Lefamulin (pleuromutulin, protein synthesis inhibitor)
Murepavadin (POL7080; peptide mimetic, LPS inhibitor)
SPR741 partner antibiotic (cationic potentiator)
TOTAL

Novel
Agents*
1

Novel
MOAs
0
No
0
No
1
YES
No
0
No
No
0
No
No
0
No
1
No
No
No
YES
No
5

1
2
2
2
1
5

42

Novel
Targets
0
No
0
No
0

Early Stage
(Phase 1)
0

0
No
No
0
No
No
0
No
1
No
No
No
YES
No
1

0

0
0

1
Phase 1
0
1

Phase 1
7

Status
Late Stages
(Phase 2 to 3)
0
1
NDA
2
Phase 2
Phase 2
0
1
Phase 3

Recently
Approved
1
2018
0
0
2
2014
2014
0

1
Phase 2
4
NDA
Phase 3
NDA
Phase 3

0

21

12

0

Does not include “novel” combination products comprised of multiple non-novel agents.
DHFR, dihydrofolate reductase; LPS, lipopolysaccharide; MOA, mechanism of action; NDA, new drug application; FAS-II, bacterial
fatty acid biosynthesis pathway.
Data sources: Jones, J. A., Virga, K. G., Gumina, G. & Hevener, K. E. Recent Advances in the Rational Design and Optimization of
Antibacterial Agents. Medchemcomm 7, 1694-1715, https://doi.org/10.1039/C6MD00232C (2016).1
Talbot, G. H. et al. The Infectious Diseases Society of America's 10 x '20 Initiative (Ten New Systemic Antibacterial Agents FDAapproved by 2020): Is 20 x '20 a Possibility? Clin Infect Dis, https://doi.org/10.1093/cid/ciz089 (2019).6
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two next generation cephalosporins that were recently approved and two in late-stage
development (Phase 2 or Phase 3) in the U.S.6
Next generation beta lactamase inhibitors
The development of two new classes of ß-lactamase inhibitors (BLIs) has resulted
in a much-needed respite from the steadily increasing threat of multi-drug resistant
(MDR) and pan-drug resistant bacterial infections. There are currently eight novel BLIs
of note, with four recently approved or in late-stage development, and four more in early
stage development (Phase 1).6
Next generation oxazolidinones
The oxazolidinone class of antibacterials is a fully synthetic class of agents and
has been considered a major breakthrough in antimicrobial drug development with
linezolid standing as the best-known representative.14 The recent emergence of linezolid
resistance has driven the investigation and advancement of next-generation
oxazolidinones with improved antibacterial activities and decreased adverse effect
profiles.15-17 To that aim, one novel oxazolidinone has recently been approved, and two
more are in late-stage development.6
Next generation bacterial topoisomerase inhibitors
Bacterial topoisomerases are extremely well validated as efficacious antibacterial
drug targets, and the type II topoisomerase inhibitors known as quinolone antibiotics
have proven to be one of the most practically effective antibacterial classes in recent
history. Quinolones have shown astonishing popularity over the last several decades,
perhaps contributing to the sharp rise in use, or overuse, and subsequent respective
resistance rates across the country.18 Nonetheless, bacterial topoisomerases have gained a
great deal of attention within the realm of antibacterial drug development, and several
inhibitors within this class have either been recently approved or are in late-stage clinical
trials. Additionally, this is one of the few classic targets with new antibacterial agents
being developed that showcase novel MOAs. One of these classes of new agents, known
as novel bacterial topoisomerase inhibitors (NBTIs), consequently lack cross-resistance
among pathogens possessing quinolone resistance. Additionally, the newer
spiropyrimidinetrione class has recently arisen with yet another unique mechanism of
topoisomerase II inhibition. Though discovered via whole-cell activity screens,
spiropyrimidinetriones have since been rationally optimized.19 As one would expect, the
unique MOIs of these newer classes imply accordingly unique structures, scaffolds, and
SARs. Overall, two novel bacterial topoisomerase inhibitors have recently been
approved, and five are in late-stage development. 6
Next generation tetracyclines
Tigecycline (Tygacil®; Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.,
initial U.S. approval in 2005) is the first semi-synthetic representative of a class of
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antimicrobials called glycylcyclines.20 The design and synthesis of glycylcyclines were
intended to overcome the major problems of modern ribosomal protection and effluxpump-mediated tetracycline resistance.21,22 The success and utility of tigecycline, coupled
with climbing resistance rates against other major antibacterial classes, have recently
prompted the development of several more novel tetracycline analogues, including two
recently approved agents and one in early stage development.6
Next generation macrolides
Macrolide antibiotics are natural product-based antibacterials composed of a
large, macrocyclic lactone core, to which a variety of sugar substituents may be attached.
Disadvantages of the macrolide antibiotics include limited Gram-negative activity, acid
instability limiting the oral effectiveness of some compounds in the class, and interaction
with human drug metabolizing enzymes in the cytochrome P-450 system that can result
in significant drug interactions.23 Further, emerging resistance, typically due to
alterations of the macrolide binding site on the ribosome, has limited the clinical utility of
older compounds in the class and, therefore, novel modified ketolide antibacterials have
been developed to overcome such issues. To date, three novel macrolides are currently in
late-stage development.
Next generation aminoglycosides
Development of next-generation aminoglycosides has been somewhat limited.
Nonetheless, semi-synthetic techniques have been implemented to develop a single novel
aminoglycoside, plazomicin. It has shown activity against a broad range of Gram-positive
and Gram-negative organisms, including ESBL-producing pathogens, when used in
combination therapy with other antibacterial agents.24 Plazomicin is not active, however,
against organisms harboring aminoglycoside resistance due to the expression of
ribosomal methylases.6,25 It is the sole next-generation aminoglycoside in development,
and was very recently approved.6
Novel bacterial folate synthesis inhibitor
Iclaprim (Motif Bio, PLC) is the sole next generation dihydrofolate reductase
(DHFR) inhibitor in late-stage development. It was rationally designed using structural
data and molecular modeling, and has potent Gram-positive bactericidal activity that
includes activity against methicillin-sensitive S. aureus (MSSA), MRSA, and
trimethoprim-resistant F98Y mutant strains.26,27 Activity against Gram-negative and
atypical organisms is reported to be similar to that of trimethoprim.28 Iclaprim was
granted qualified infectious disease product (QIDP) status and is in the NDA stage.6
Novel inhibitors of the bacterial FAS-II pathway
Two promising anti-staphylococcal FabI inhibitors are currently under
development, both of which represent notable rational design methods. The first
compound, CG400549, was designed to overcome the unfavorable pharmacokinetics of

9

triclosan by replacing a metabolically unstable phenol group with a pyridone ring system
and the small ether linker with a methylene group.29,30 CG400549 binds to the FabINADPH (reduced cofactor) binary complex, making the drug uncompetitive with respect
to NADPH binding and competitive with respect to the binding of the FabI enoyl
substrate. The other FabI inhibitor in development, afabicin (Debio-1450) was developed
using a classically iterative, structure-guided strategy, and showcases a unique MOA
where the agent binds to a binary complex of the enzyme and its oxidized cofactor,
NADP+.31-33 Modern structural information has guided recent efforts to expand the
activity of CG400549 by iterative, structure-guided design strategies, to include Gramnegative pathogens and mycobacteria.29 Both GC400549 and afabicin are in late-stage
development.6
Novel lipoglycopeptides
The lipoglycopeptides contain large lipophilic moieties linked to glycopeptides,
making their molecular weight notably high and, therefore, inherently separate from
“small molecule” antibacterials.34 Nonetheless, two lipoglycopeptides with notable
Gram-positive activity, dalbavancin and oritavancin, were approved within the last five
years.6
Novel penems
The carbapenems are ß-lactam antibacterials developed several decades ago that
showed exceptional activity against MDR bacteria.35 Their use has become more limited
over the years, though, as resistance to the class was observed very soon after their
clinical emergence.36 Recent development of novel penems has resulted in one agent in
early stage development and one oral agent in late-stage development.6
Novel monobactam
Monobactams were discovered several decades ago, with the prototype aztreonam
showcasing, as the class name would indicate, an unfused ß-lactam ring.37 While
aztreonam is susceptible to serine beta lactamases, the novel monobactam LYS228 shows
greater stability against SBLs and is currently in late-stage development.
Other novel agents
While more difficult to classify, several other novel antibacterial agenta are
currently under development. These include the cell wall synthesis inhibitor fosfomycin,
currently undergoing NDA status; the protein synthesis inhibitor fusidane, known as
fusidic acid, currently in late-stage development; the pleuromutlin protein synthesis
inhibitor known as lefamulin, currently in NDA status; the cationic, Gram-negative outer
membrane targeting potentiator known as SPR741, currently in early-stage development;
and Murepavadin (POL7080, Polyphor, Ltd.), which is a synthetic beta hairpin
peptidomimetic with anti-pseudomonal activity currently in late-stage development and
is, notably, the only novel antibacterial agent with a truly novel target.6,38 It is worth
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mentioning, however, that as a peptide, this agent is not a small molecule antibacterial,
per se.
The Narrow Spectrum Era
Current techniques and methods being implemented in the rational design and
optimization of antibacterial agents suggest a subtle change in the recent state of affairs
regarding the struggle against bacterial infections. As described above, recent advances in
various techniques have helped gain small amounts of ground in the modern struggle
against resistant bacterial infections—a conflict where prolonged trends have mostly
demonstrated losses. Promising standouts include specific chiral configurations of new
quinolones that grant improved activity under acidic conditions, fully-synthetic
techniques used in the next-generation tetracyclines that allow for novel side-chains that
grant activity against resistant pathogens, and semi-synthetic techniques used in the nextgeneration macrolides that allow for the modification of functional groups that improve
binding and, again, activity against resistant pathogens. The recent advances in the
rational design and optimization of antibacterial agents are both encouraging in the fact
that the downward trend in FDA approvals has been, if not reversed, at least momentarily
slowed. Nonetheless, results are also somewhat discouraging in the fact that up until this
point, all recent approvals lack novel targets.
With newly implemented incentivization and modern advances in research
methods, it is hoped that the threat of antibacterial resistance will continue to be met with
appropriate countermeasures. The number of novel antibacterial agents that were recently
approved or under late-stage development is highly encouraging, as is recent U.S. and
European legislation facilitating the rapid development and approval of new
antibacterials. By 2016 alone, there were almost 60 antimicrobial drugs granted QIDP
status in the U.S., six of which had already attained U.S. approval, and 37 that were in
late-phase clinical trials. In the last ten years, twelve new antibacterial agents were
approved and, by 2019, three agents were in NDA status.6 These results stand as evidence
for the initial success of these new initiatives and their ability to drive the advancement of
antibacterial development. As mentioned above, however, a thorough analysis of the
antibacterial pipeline showcases a trend that is still somewhat troubling. While there has
been a noteworthy increase in antibacterial drug discovery and development, the
astonishingly low number of compounds under development with original targets
highlights the urgent need for the characterization and validation of such.
This need for novel, validated targets has been emphasized by numerous reports
from public health agencies across the world indicating the fact that resistance to
antibacterial agents that exploit traditional targets continues to surge. Just within the last
several years, the CDC reported a fatality within the United States resulting from a strain
of New Delhi metallo-ß-lactamase (NDM) possessing Klebsiella pneumoniae found to be
resistant to 26 antibiotics, including every aminoglycoside and polymyxin agent tested,
and possessing what is assumed to be a novel resistance mechanism to the commonly
regarded “antibiotic of last resort,” colistin.39 Despite encouraging progress being made
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with optimization strategies, relying on classic antibacterial targets alone is simply not
enough. It has been argued that ample attention should be turned toward the future
development of selective antibacterial targets, a move that is expected to bolster the
antibacterial pipeline as well as slow the development of antibacterial resistance. It is
reasonable to believe that antibacterial agents geared toward such selective targets would
have substantial additional benefits—such as the possibility of developing effective
microbiome-sparing agents and the requirement for rational, more responsible use of
antibacterial agents that would in turn contribute to greater antibacterial stewardship. This
is giving way to what some predict will be the next phase of antibacterial discovery and
development—the “narrow spectrum-era.”2 While indeed an exciting prospect,
characterizing and validating novel narrow-spectrum targets would of course require an
understandably substantial amount of intellectual resources, innovation, and effort
previously unseen—including fully rational drug design based around heretofore novel
and unconventional targets, the employment of a broad arsenal of drug discovery skills
and techniques (Figure 1-2), and a certain degree of anticipated success.
Requisite Antibacterial Drug Discovery Skills and Techniques
Target identification and production techniques
Techniques involved with preliminary target identification include a thorough
literature review in order to survey the successes, failures, difficulties, and considerations
of researchers who may have already pursued similar research paths; genomic
bioinformatics techniques for data mining the existence of genes of interest for rational
targets in pathogens of interest, as well as comparative genomic techniques for assessing
the absence or existence of respective selective or otherwise rational targets in other
bacteria; other bioinformatic techniques that allow one to assess certain parameters of the
target that will later prove invaluable during target production, characterization, and
compound screening—parameters such as target size, stability, isoelectric points,
extinction coefficient, solubility, and lipophilicity.
Once a satisfactory rational target has been selected that confers a particular
degree of anticipated success, techniques centered around target production become of
immediate importance. First, cloning techniques are required to produce the gene of
interest that codes for the particular target enzyme. First, the gene must be acquired, must
commonly done by polymerase chain reaction (PCR) amplification. Different cloning
techniques must then be used to transfer the gene of interest into a suitable expression
vector. Such cloning techniques include classic restriction enzyme cloning, TOPO
cloning, TA cloning, Gibson cloning, Gateway cloning, ligation-independent cloning
(LIC), and others. Decisions regarding codon optimization for anticipated expression
organisms must also be considered at this point. Alternatively, the gene and an
appropriate vector may also simply be purchased. As with all research, a cost analysis of
time, money, manpower, and perhaps learning opportunity must be taken into account
when selecting the most suitable technique. Additionally, decisions on later expression
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Figure 1-2. Drug discovery skills and techniques used in the investigation of
narrow spectrum targets in antibacterial drug discovery.
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and purification techniques must be considered here, as an appropriate vector must be
selected that carries the appropriate induction methods to produce the target enzyme, as
well as the appropriate tags desired for solubility, recognition, purification, etc. Once the
gene of interest is produced and has been inserted into a satisfactory vector, it must be
transformed into a production host, such as bacteria (most commonly Escherichia coli),
yeast, insect, or mammalian cell lines.
Next, protein production techniques become imminently necessary. This includes
growth and induction techniques, such as classic isopropyl-ß-D-1-thiogalactopyranoside
(IPTG) induction, tetracycline induction, or autoinduction, among others. Target protein
can then be harvested and purified via a number of various popular techniques,
ammonium sulfate precipitation, immobilized metal affinity chromatography (IMAC),
ion exchange chromatography, hydrophobic interaction chromatography (HIC), and sizeexclusion chromatography (SEC) among some of the most popular. Numerous other
techniques are available, including more costly, but also highly specific antibody directed
purification systems. A researcher can also use resins and slurries that apply his or her
purification modality of choice under gravity filtration, or choose pre-packed columns
and fast protein liquid chromatography (FPLC) systems for higher throughput and
convenience. and expertise in protein biochemistry and purification make it possible to
tailor the purification protocol to the characteristics and needs specific to a particular
rational target. Upon determination of a rational antibacterial target and its subsequent
procurement, it should be immediately and fully engaged. While multiple steps exist
during such engagement, it is somewhat difficult to list a definitive order for proper
execution of such and, therefore, a certain degree of adaptability is required. Nonetheless,
the techniques essential for further pursuit follow, but are not in a definitive order and,
instead, all have the potential to contribute a portion of all knowledge required for
successful rational antibacterial drug discovery and development.
Preliminary target characterization
While every protein is different, some targets may be inherently stable and
immediately easy to work with, while others prove recalcitrant to many conditions and
procedures from the moment they are purified. Such intractability may prove not only
inconvenient, but altogether discordant with the timeline a research team is under.
Therefore, it is of the utmost benefit to characterize the target protein, and any constructs
created, as soon as possible in order to move forward as efficiently as possible. As such, a
number of techniques exist to aid in such hasty pursuits.
General techniques. Several miscellaneous techniques exist for the preliminary
characterization of a purified target protein that may be of some service to a research
team. While much information can be determined about the protein of interest from the
aforementioned application of bioinformatics and literature searches, techniques exist to
corroborate calculated protein parameters or, often times, determine a characteristic more
precisely. Examples include, but are not limited to, isoelectric focusing to determine a
precise isoelectric point that could prove highly useful during stability assessments;
denatured or native polyacrylamide gel electrophoresis (PAGE) for determining sample
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purity, analyzing degradation, or evaluating dimerization; analytical gel filtration
chromatography, or analytical SEC, for analyzing purity, size, dimerization, and other
global characteristics of a target protein, such as whether or not it is retaining a bound
cofactor or not; and mass spectrometry (MS), which offers an enormous amount of
knowledge about the target, from identification via peptide fingerprinting, to de novo
sequencing of an unknown target, to general structural inferences, to protein-protein
interaction analyses via cross-linking MS.40,41 While only a few examples of general
preliminary techniques, these highlight the importance of possessing a thorough working
knowledge of protein biochemistry and the tools available for one’s use in thoroughly
analyzing and characterizing a target protein in early-stage antibacterial drug discovery.
Thermal shift assay. Another popular and very useful early-stage target
characterization technique resides in the thermal shift assay, or differential scanning
fluorimetry (DSF). This technique should be employed as early as possible as it may
allow for subsequent analyses to occur that, without stable target protein, may not be
feasible. Mastery of this technique is actually dually beneficial, as it can be used to
identify ligands that bind to the purified target enzyme, thereby stabilizing the protein and
increasing its melting temperature—which is determined by a hydrophobic fluorescent
dye binding to the similarly hydrophobic innards of the target protein that are exposed
upon melting and resulting in a measurable increase in fluorescence—or it can simply be
used to identify salt, polyol, buffer, pH, or additive conditions that stabilize the protein,
making further work notably easier.42
Compound screening and hit selection techniques
After purified stable, homogenous target protein is acquired, one of the next
rational drug discovery steps is compound screening and selection of hit compounds for
the sake of assessing how “druggable” the target is—meaning how likely is it that the
target is accessible to a small molecule that can elicit a measurable biological response of
biological and, potentially, clinical import. Once again, an immediately initial technique
worthy of noting with respect to compound screening and hit selection is simply a
thorough literature review.
Active compound literature review. During early screening, it may be possible to
find previous hits or compounds discovered or developed previously against related or
otherwise similar targets by other research groups that may also be active against a novel
rational target of interest. Even if such a compound does not show similar activity against
the new target, it may prove useful as a chemical probe with utility later on in target and
hit validation and characterization, or as a scaffold for iterative lead development and
structure-activity relationship (SAR) analyses. Whether or not such an asset may be
exhumed from the literature for any given rational drug discovery campaign, a battery of
other useful drug discovery techniques prove to be absolute necessities.
Biophysical techniques. For truly novel antibacterial targets, previous inhibitors
or chemical probes simply may not be known, or may not even exist. What is more, highthroughput screening (HTS) assays may not be developed, either. Also, knowledge of
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conditions necessary for the stabilization of the targeted protein may not be immediately
available. Nonetheless, a reasonable starting point in the search for useful chemical
probes may be found in a more medium throughput method, or even a low throughput
method under the most dire of circumstances.
As mentioned above, the thermal shift assay technique is of significant utility
during early stages of antibacterial drug discovery for the sake of preliminary protein
characterization. While extremely useful for identifying stabilizing conditions for the
novel target, the utility of the thermal shift assay in finding ligands that bind the enzyme
is also substantial, but must be pursued cautiously. The reason for this is that just because
a compound is discovered that binds the enzyme as a ligand, and therefore shifts the
melting temperature higher, does not guarantee it has any activity, such as agonism or
antagonism. As such, the discovery of such a compound would unquestionably call for
further analysis and highlights the need for the use of a known functional assay or, if the
existence for such does not exist, the requisite development of such.
Lower throughput techniques used for the study of ligand-protein binding
interactions include surface plasmon resonance (SPR; low to medium throughput) and
isothermal titration calorimetry (ITC; lowest throughput of methods discussed). SPR
requires the first protein binding component be immobilized on a sensor chip as the other
test-compound binding component is free in solution and passed over the first component
while subtle differences in refractive index are detected at the surface of the sensor.43
ITC, on the other hand, simply uses heat as a signal to quantitatively measure binding
affinity (Ka), stoichiometry (n), and enthalpy change (ΔH), after which free energy
change (ΔG) and entropy change (ΔS) can be calculated.44 While lower throughput, both
of these techniques benefit from the fact that neither requires labeling of any sort.
Biochemical techniques. HTS methods are desirable in order to increase
efficiency in the search for hits against a rational target. Biochemical assays are naturally
more amenable to supporting higher throughput screening than their biophysical
counterparts. In contrast to biophysical assays, biochemical assays allow not only for the
measurement of the affinity of test compounds for purified target protein, but also for the
measurement of some biologically meaningful effect related to the overall function of the
target enzyme.45 Moreover, biochemical assays can often be read in small volumes
compliant high throughput plates and plate readers that make large numbers of repetitive
assays possible, thereby introducing the possibility of screening entire libraries in very
little amounts of time and covering as much chemical space as possible in the search for
active compounds. Often, assays exist or can be developed that rely upon the
measurement of some easily recorded change in absorbance, fluorescence, or
luminescence via the exploitation of reactions involving components such as metabolic
cofactors, fluorophores, and quenchers. Such assays not only allow for high throughput
chemical library screening, but also allow for efficient target and hit validation.
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Target and hit validation and characterization techniques
Once hit compounds are determined, a more thorough analysis of the target
enzyme and the hit compound, as well as the interactive relationship between the two,
can commence. A number of techniques exist to this end, and while it may be nearly
impossible for a single lab or researcher to have a mastery of all of the following
techniques, as well as access to the necessary respective instrumentations, the more
techniques that can be employed, the more thorough understanding and knowledge
pertaining to the target will be afforded. At minimum, however, a well-balanced and
complementary combination of the following techniques are necessary.
Structural biology techniques. Various structural biology techniques exist that
may be used for further biophysical characterization of a target protein and any
significant interactions the target protein may make with various ligands. As would be
expected, each technique carries with it its own benefits and liabilities, including
administrative attributes like ease of use, access, and cost, as well as actual benefits and
liabilities associated with the actual nature of the techniques and the application and
results that can be expected from each.
X-ray crystallography. Considered the most powerful structure-guided drug
discovery tool, X-ray crystallography offers a multitude of knowledge about the target
protein down to the atomic level, with some crystal structures even determined and
deposited in the protein data bank (PDB) with resolution below 1 Å.46 While structures at
this high of a resolution are not overwhelmingly common, numerous structures exist in
the PDB near the 2 Å resolution level, which allows not only overall structural features to
be observed, but also finer features like peptide side chains and atomic interactions
critical for structure-guided drug discovery. Cons to X-ray crystallography include the
need to crystallize the target protein which, depending on the protein, may take
substantial amounts of time (or simply never occur), may not yield high-quality
diffracting crystals, and may not necessarily represent a biologically relevant
conformation of the target protein; the need for access to a high-power X-ray source; as
well as the substantial learning curve involved in procuring pure, homogenous protein,
attaining high resolution diffracting crystals, data collection, data processing, and
refinement. Nonetheless, the benefits of X-ray crystallography continue to outweigh the
costs as it remains the indisputable golden standard for protein structure analysis.
Cryo-electron microscopy. Quickly becoming one of the most popular and
powerful structural biology techniques available, cryo-electron microscopy (cryo-EM)
has recently undergone substantial hardware, software, and methodology improvements
that allow for near-atomic resolution biomacromolecular structure determination.
Benefits of cryo-EM include the fact that the target protein does not need to be
crystalized, which saves a substantial amount of time for the researcher and also allows
structural analysis of the protein in an arguably more “biologically relevant,” or “near
native” state.47 Limitations nonetheless include the requirement for pure, stable, and
homogeneous protein; access to expensive equipment; substantial expertise; lower
resolution structure determination relative to X-ray crystallography; and a high target
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protein molecular weight cutoff limit relative to other major structural biology
techniques.48 Though these last two issues represent major historical barriers to cryo-EM,
which have traditionally included difficulty crossing the 2 Å resolution barrier and
difficulty determining the structure of target proteins smaller than ~200 kilodaltons
(kDa), recent reports exist of instances where the technique indeed produced results that
broke each of these proposed barriers.49 As such, this technique is understandably gaining
momentum, offering some utility in rational drug discovery efforts, with the potential for
even greater utility to come.
Nuclear magnetic resonance spectrometry. Perhaps the final main structural
biology technique worth discussing, nuclear magnetic resonance (NMR) spectrometry
adds a significant amount of knowledge that complements the aforementioned techniques
very well. While limitations indeed exist, such as a requirement for soluble protein,
access to equipment and expertise, and a less practical general maximum target protein
size cutoff limit of roughly 25 kDa, NMR is an extremely powerful modern tool used in
drug discovery efforts. Unlike the other techniques mentioned, NMR offers the ability to
characterize highly dynamic and disordered target proteins, the ability to analyze target
enzyme activity in real-time, and the ability to effectively map specific binding site
characteristics, among others.50-52
Enzymology techniques. Thorough target protein characterization and validation
requires a variety of different enzymology techniques. Functional biochemical assays are
an absolute requirement for proper analyses of compound potency and the evaluation of
mode of inhibition. A return to biophysical assays like thermal shift, ITC, and SPR is
necessary for a proper assessment of binding kinetics.
Iterative lead development techniques
As the realistic terminal goal of any rational drug discovery campaign is the
eventual development of lead compounds that can be carried on to clinical development,
a fair amount of iterative rational compound optimization must occur. As a culmination
of all pre-clinical development up to this point, it is understandable that SAR-guided
chemical optimization should include all techniques heretofore discussed, as well as a
few additional techniques.
SAR-guided chemical optimization. Thorough analysis of structural data, ideally
with a bound ligand, affords the researcher the opportunity to visualize the target enzyme
and its corresponding active or allosteric site along with a previously discovered or
developed ligand. This will allow for rational modification to the compound that allows
the researcher to manipulate the compound to maximize characteristics like potency via
improved or added non-covalent molecular interactions, solubility via rational addition of
solubilizing groups at key positions, and so on. This allows for medicinal chemistry trials
to commence, where newly synthesized rationally modified compounds can be tested via
in vitro or in vivo functional assays.
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Virtual screening. Additional methods can also take place once structural data is
obtained, including virtual screening, where significantly large computational libraries
can be prepared and screened against the target protein via techniques like docking,
pharmacophore matching, and shape matching. Any possibly improved and optimized
compounds that result can then be synthesized or purchased and, again, tested against the
target protein for potency assessment.
Any gains or losses that result after classic “manual” SAR-guided optimization or
virtual screening regarding potency and physicochemical attributes can be rationally
weighed and evaluated. Then, the products can be rationally analyzed and further
modified in an iterative fashion until a satisfactory product results that has, ideally,
balanced an increased potency with satisfactory physicochemical properties that will not
hamper the compound with respect to toxicology, metabolism, pharmacokinetics, or
pharmacodynamics during future clinical trials and development.
While it is unlikely that a researcher or research team would have access to
expertise and equipment needed for every technique discussed above, a working
combination is required and must be tailored to the specific rational target. Pros and cons
of each technique must be considered, and a respectively appropriate research plan
should commence based around which techniques are needed for project success and
which techniques are available. While some techniques are absolute necessities, such as
bioinformatics and protein production and purification, some but not all representatives
from the other overarching technique categories can be mixed and matched. For example,
depending on the specific research needs, while access to SPR may not exist, ITC may
take its place; while cryo-EM may not be suited for a smaller protein target, X-ray
crystallography may work well; and while biochemical assays utilizing absorbance may
not be feasible, development of chemical probes or substrates that utilize specific
fluorophores may be a possibility. As with most endeavors, the more knowledge and
expertise one possesses, the more adaptability is afforded, and the more anticipated
success exists. Consequently, it is arguable that access to enough knowledge, skills, and
instrumentation would allow for any novel target to be engaged.
Novel Narrow Spectrum Antibacterial Targets
Whether the novel antibacterial target of interest is intended to be a broad
spectrum target, a narrow spectrum target, or simply “anything we can get,” knowledge
about the target itself is of paramount importance. In fact, before the actual pursuit
begins, it is understood that a substantial amount of resources—time, energy, money—is
going to be invested into the target. That is why, as mentioned above, a certain degree of
anticipated success must accompany any real antibacterial drug discovery and
development campaign. But, how can a researcher anticipate success when so little is
known about a previously un-elucidated target? The only way, in fact, is to harvest as
much knowledge about the target of interest in advance. This is, of course, important
during rational drug discovery and development, but absolutely crucial when pursuing
narrow spectrum antibacterial targets.
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Pertinent questions include, but are not limited to, is the antibacterial target
essential, or does its function at least dictate a significant degree of fitness to its host
organism that could be exploited in some clinically significant manner? Perhaps it is an
explicitly essential enzyme target. Or, perhaps it is instead a more cryptic target that
confers some degree of fitness that can be taken advantage of and leveraged in high-stress
biological situations, such as during immune response, concomitant antibacterial agent
administration, or human microbiome supplementation and overcrowding. With respect
to potential narrow spectrum targets, another pertinent question involves the existence—
or rather the absence—of the target in other bacteria that represent the beneficial
members of the human microbiome. For the sake of selectivity, multiple beneficial
scenarios could exist. First, it would be ideal if the target existed only in the genomes of
only a few pathogens, thereby sparing beneficial bacteria from collateral damage and
eradication. Alternatively, the gene responsible for the target enzyme could exist in
bacteria other than the target pathogen, but perhaps the non-targeted bacteria possess
bypass mechanisms that render that particular target non-essential in the respective
bacteria under physiological conditions.
Other pertinent preliminary questions of course involve the overall nature of the
pathogen being targeted, such as site of infection, gram-stain classification, absence or
presence of efflux pumps, and extent of pathogenicity. These types of questions may help
guide anticipated physicochemical characteristics necessary for any future chemical
probes or inhibitors, amongst others. Altogether, it is evident that the more preliminary
knowledge a researcher has before commencing a rational antibacterial drug discovery
campaign, the better. Once a requisite amount of preliminary knowledge is gained, a
number of actual laboratory-based techniques are required for the successful discovery
and development of rational antibacterial agents.
Again, as our understanding of the human microbiome evolves, the deficiencies in
traditional, broad-spectrum antibacterial therapy are becoming increasingly apparent.
Both the advent of multi-drug resistant bacterial infections and the devastating
disturbance of our normal bacterial ecology testify of the alarming need for novel
antibacterial agents capable of selectively targeting pathogens, drug-resistant or
otherwise, while mitigating the impact on beneficial and commensal organisms. As such,
the benefit of narrow spectrum targets, which may afford opportunities for the killing or
inhibiting specific pathogens without significantly inhibiting the growth of collateral or
beneficial bacteria, is substantial. Engaging enzyme targets that meet these requirements,
however, hinges upon exploiting intrinsic differences between the enzymatic proteomes
of pathogenic bacteria and commensal bacteria—differences can be notably difficult to
discern, thereby making the identification of such narrow spectrum antibacterial targets
appropriately difficult.53,54 Two such potential targets follow.
Bacterial topoisomerase I
Bacterial topoisomerase I represents a potentially promising narrow-spectrum
target as studies have arisen demonstrating its essentiality in bacterial species lacking the
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only other type IA topoisomerase (topoisomerase III). With evidence supporting the
bacterial essentiality of at least one type IA topoisomerase (topoisomerase I or
topoisomerase III), an overlapping role between the two enzymes, and the fact that a
select few pathogenic bacterial species solely possess topoisomerase I without
topoisomerase III, the catalytic inhibition of bacterial topoisomerase I represents an
attractive prospect for novel, selective antibacterial development.55-59 The streptococci
are one of the few bacterial species that may possess topoisomerase I as their sole type IA
topoisomerase and a representative, Streptococcus mutans, exists as a particularly
promising candidate for the exploration and validation of topoisomerase I as a novel,
selective antibacterial target.60-66
Bacterial enoyl-acyl carrier protein (ACP) reductase II, FabK
Bacterial enoyl-acyl carrier protein (ACP) reductase II, or FabK, is an enzyme
within the bacterial fatty acid biosynthesis (FAS II) pathway that represents another
highly promising narrow-spectrum target. Recent studies have demonstrated the
essentiality of fabk gene that codes for enoyl-ACP reductase II (FabK) in C. difficile.67
FabK is one of several disparate enoyl-ACP reductase isozymes (FabI, FabK, FabL, and
FabV) that exists across bacteria.68-70 Additionally, recent data has shown that different
regulatory systems control whether or not a bacterium is capable of bypassing FAS II
inhibition via the uptake of exogenous fatty acids.71,72 Because FabK is the sole, essential
enoyl-ACP reductase expressed in C. difficile, combined with the fact that different
bacteria may possess an assortment of other enoyl-ACP reductase isozymes and
regulatory systems, FabK from C. difficile represents a potential antibacterial target with
particularly significant narrow-spectrum promise.
Presented here are data investigating both the bacterial topoisomerase I and FabK
enzymes as novel and potentially narrow spectrum antibacterial targets via validation and
characterization studies using an array of drug discovery techniques, including structural
investigations, biochemical assay development and application, and inhibitor screening
and testing.
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CHAPTER 2.

TARGETING BACTERIAL TOPOISOMERASE I2
Introduction

Topoisomerases Background
Biological role of topoisomerases
Topoisomerases are ubiquitous enzymes that help manage the diverse topological
complications DNA undergoes during various biological processes. In general, the
overall mechanism by which all topoisomerases function is centered around the initiation
of controlled breaks in the DNA via temporary phosphodiester bonds between the
substrate and a conserved catalytic tyrosine residue on the enzyme.73-75 The topological
complications managed include negative and positive supercoils, catenated DNA rings,
and various entanglements.75 There are a number of different topoisomerases that exist
across all forms of life, which are organized into particular types and subtypes and serve
varying biological roles. These roles may or may not overlap to a certain degree as they
are carried out to address the different aforementioned topological complications in
particular ways (Table 2-1).55,75-78 Type I topoisomerases exist as monomers that cause
single DNA strand breaks and elicit topological change one link at a time via either a
rotational or strand passage mechanism, and type II topoisomerases are multimers that
require adenosine triphosphate (ATP) hydrolysis as an energy source in order to initiate
double stranded breaks and facilitate DNA strand passage; whereas subtype A
topoisomerases result in a 5’ phosphotyrosine DNA cleavage intermediate, and subtype B
topoisomerases result in 3’ phosphotyrosine intermediates.55,75,79 Accordingly,
topoisomerases are indispensable in their biological duties and, therefore, represent
highly attractive and efficacious chemotherapeutic targets. While many human
topoisomerases exist as well-validated and exploited anti-cancer targets, only a select few
bacterial topoisomerases are currently exploited as useful antibacterial targets.
Different bacterial topoisomerase targets
Up to four topoisomerases can be present in the prokaryotic genome, two from the
type IIA family and two from the type IA family. Type IIA topoisomerases are
heterotetramers encoded by multiple genes (gyrA/B and parC/E), and type IA
topoisomerases are monomers encoded by single genes—topA for topoisomerase I
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Adapted from final submission with permission from Elsevier Inc. Jones, J. A., Price, E., Miller, D. &
Hevener, K. E. A simplified protocol for high-yield expression and purification of bacterial topoisomerase
I. Protein Expr Purif 124, 32-40, https://doi.org/10.1016/j.pep.2016.04.010 (2016).73
Adapted from final submission with open access permission from Elsevier Inc. Jones, J. A. & Hevener, K.
E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA topoisomerase I from the grampositive model organism Streptococcus mutans. Biochem Biophys Res Commun,
https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Table 2-1.
Type

I, SS
Break

Overview of types and subtypes of select topoisomerases.
Subtype
A
B
C

II, DS
Break

A
B

Enzyme
Topo I
Topo III

Topoisomerase IIIα
Topoisomerase IIIß
Reverse gyrase
Topoisomerase I
Topoisomerase V
Topo II/Gyrase
Topoisomerase IV
Topoisomerase IIα
Topoisomerase IIß
Topoisomerase VI

Source
Bacteria
Bacteria
Mammalian
Mammalian
Archaea, other
Mammalian
Archaea
Bacteria
Bacteria
Mammalian
Mammalian
Archaea

Function
Relax - SCs
Decatenation, relax - SCs
Relax - SCs
Uncertain
Cause + SCs
Various, relax +/- SCs
Relax +/- SCs
Introduce - SCs
Relax - SCs, decatenation
Decatenation
Various
Relax +/- SCs, decatenation

Link
5’

3’

5’

Energy Source
Torsional strain
Torsional strain
Torsional strain
Torsional strain
ATP
Torsional strain
Torsional strain
ATP

Subunits
Monomer
Monomer
Monomer
Monomer
Heterodimer
Monomer
Monomer
Heterotetramer
Heterotetramer
Homodimer
Homodimer
Heterotetramer

DS, double stranded; SCs, supercoils; SS, single stranded
Data sources: Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70, 369-413,
https://doi.org/10.1146/annurev.biochem.70.1.369 (2001).75
Pommier, Y. Drugging topoisomerases: lessons and challenges. ACS Chem Biol 8, 82-95, https://doi.org/10.1021/cb300648v (2013).
Slesarev, A. I. et al. DNA topoisomerase V is a relative of eukaryotic topoisomerase I from a hyperthermophilic prokaryote. Nature
364, 735-737, https://doi.org/10.1038/364735a0 (1993).55
Wendorff, T. J. & Berger, J. M. Topoisomerase VI senses and exploits both DNA crossings and bends to facilitate strand passage.
Elife 7, https://doi.org/10.7554/eLife.31724 (2018).77
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topB for topoisomerase III.55,80 Only two bacterial topoisomerases—the type IIA
topoisomerases known as gyrase and topo IV—have inhibitors that have been developed
and marketed as antibacterial drugs.55 These type IIA topoisomerases stand as very wellestablished and well-validated antibacterial targets via the quinolone class of
topoisomerase poisons, which form bactericidal topoisomerase-DNA-quinolone ternary
complexes and result in broad-spectrum antibacterial activity. In contrast, the type IA
topoisomerases—topoisomerase I and topoisomerase III—remain relatively unexplored
from a drug discovery and development standpoint and are consequently without
respectively approved inhibitors.55 Current efforts are being undertaken, however, to
discover and develop novel bacterial topoisomerase IA inhibitors.81
As evolutionary paralogues, topoisomerase I and topoisomerase III are believed to
have arisen via gene duplication and, therefore, reasonably exemplify a certain degree of
functional overlap.82 Topoisomerase I exists in all bacteria to relax negative DNA
supercoils, while topoisomerase III is only found in some bacteria and is primarily geared
toward decatenation (Table 2-2).78 Nevertheless, it has been shown that E. coli strains
possessing the genes for both topoisomerase I and topoisomerase III (topA and topB,
respectively), while comparatively less fit, are able to survive topA gene deletion
mutations, but strains lacking the topB gene showed no such viability.83 The scientific
deduction made herein is that when topoisomerase I activity is negated in some way, the
residual topoisomerase III enzyme, if present, is capable of relieving the resultant insult,
thereby maintaining viability and fitness to some extent and acting as a sort of enzymatic
levee. This concept introduces the hypothesis that, on top of the potential broad-spectrum
fitness cost of topoisomerase I inhibition across all species of bacteria, specific
topoisomerase I inhibitors could have the added effect of showing selectivity against
organisms that possess the topA gene in absence of the topB gene (Figure 2-1).
Type IA Topoisomerases in Streptococci
Several clinically relevant bacteria exist that possess topA without topB and,
therefore, express topoisomerase I as their sole type IA topoisomerase. Examples include
Acinetobacter baumanii, Francisella tularensis, Helicobacter pylori, Legionella
pneumophila, Mycoplasma pneumoniae, and Mycobacterium tuberculosis.78 The
clinically relevant streptococci were also long thought to possess topA without topB.
However, recent provisional streptococcal topoisomerase III protein sequence depositions
in the National Center for Biotechnology Information (NCBI) database have surfaced that
now suggest otherwise. Further bioinformatic analysis, though, suggests at least the
possibility that the streptococcal topo III protein sequences found in NCBI may be
misannotated as there is no NCBI-annotated streoptococcal topB gene.84 Furthermore, a
Basic Local Alignment Search Tool (BLAST) nucleotide-to-nucleotide “blastn” analysis
of the E. coli topB gene (accession no. CP009685.1) against the genome of the Grampositive model organism Streptococcus mutans (taxid: 1309), returned no significant
similarities.84,85 Similarly, a BLAST protein-to-nucleotide “tblastn” analysis of the
provisionally annotated S. mutans topo III protein (accession no. SUN72613.1) from
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Table 2-2.

Topoisomerases present in clinically relevant bacteria.

Species

Topoisomerase Topoisomerase Gyrase
I
III
S. mutans
X
?
X
A. baumannii
X
X
F. tularensis
X
X
H. pylori
X
X
L. pneumophila
X
X
M. pneumoniae
X
X
M. tuberculosis
X
X
B. anthracis
X
X
X
C. difficile
X
X
X
E. coli
X
X
X
E. faecalis
X
X
X
H. influenzae
X
X
X
K. pneumoniae
X
X
X
N. gonorrhoeae
X
X
X
P. aeruginosa
X
X
X
S. aureus
X
X
X
Y. pestis
X
X
X

Topoisomerase
IV
X
X
X
X
X
X
X
X
X
X
X
X
X
X

Data source: Forterre, P., Gribaldo, S., Gadelle, D. & Serre, M. C. Origin and evolution
of DNA topoisomerases. Biochimie 89, 427-446,
https://doi.org/10.1016/j.biochi.2006.12.009 (2007).78

25

Figure 2-1.

S. mutans topoisomerase I structural homology model.

Full structure of the SmTopoI enzyme (blue ribbons) with the N-term (green) and flexible
C-term domain highlighted (red).
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NCBI against the S. mutans UA159 genome (taxid: 210007) only showed a 27.6%
identity match with the S. mutans complete genome (accession no. AE014133.2), which
may possibly represent a low-grade match to the nucleotide sequence for another DNAbinding enzyme from S. mutans such as, but not necessarily, topA.84,85 An open proteinto-protein “blastp” search of the NCBI annotated S. mutans topo III protein (accession
no. SUN72613.1), however, returned a substantial number of topo III protein sequence
matches from other streptococci that range from 65.46 to 98.45%.85 While an uncertainty
indeed lingers around the presence or absence of topB in S. mutans, substantial utility still
remains in studying the topo I enzyme from this useful organism.
If S. mutans does in fact possess topo I as its sole type IA topoisomerase, then it
would serve as a particularly promising subject for the validation of topo I as an effective
narrow-spectrum antibacterial drug target. In contrast, if it turns out S. mutans actually
expresses topo III as well, topo I from S. mutans (SmTopoI) may, for the time being, still
act as a useful surrogate antibacterial target for amassing information regarding the
druggability of topo I that may later be translated to other bacteria that are confirmed to
express topo I as their sole type IA topoisomerase. Therefore, either way, the
investigation of SmTopoI serves as a promising head start for the characterization and
validation of topoisomerase I as a selective antibacterial target. This research thereby
endeavors to use S. mutans to address remaining gaps in knowledge relating to key
structural evidence substantiating the druggability of topoisomerase I in general.
As a representative of the viridans group streptococci (VGS) and a Gram-positive
model organism, S. mutans exists as an excellent candidate for the initial exploration and
validation of topo I as a novel antibacterial target.60-66 VGS are represented by a plurality
of heterogeneous streptococcal organisms that constitute a common component of the
human microbiome found primarily within the oral cavity and upper respiratory tract, as
well as in the gastrointestinal tract and female genitourinary tract.86,87 With historically
low consideration for pathogenicity, VGS have been increasingly implicated in a wide
array of problematic diseases such as endocarditis, pneumonia, cellulitis, bacteremia, and
viridans streptococcal shock syndrome, among others.86,88 Moreover, VGS stand as the
predominant group of microorganisms within the oropharynx, with a member of the
group, S. mutans, representing the main culprit in dental cariogenesis.89 Considering the
vast clinical and economic burdens now known to be caused by VGS, the necessity for
effective antibacterials targeting these pathogens has escalated. While the majority of
VGS infections are still susceptible to penicillin, the proliferation of drug-resistant VGS
organisms, including those resistant to penicillins, macrolides, and lincosamide
antibiotics, is becoming more of a concern.86,87 Additionally, as the beneficial bacteria
that cohabitate the usual sites of VGS residence are concomitantly eradicated by the
traditional use of these broad-spectrum antibacterials, significant collateral consequences
such as candidiasis and Clostridioides difficile infections have increased over time.90-92
Therefore, novel targets for new VGS-focused antibacterials are in dire need.
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Targeting SmTopoI
As most bacterial topo I inhibitors published to date are general DNA-binding
agents, they would be expected to show poor selectivity for individual type IA
topoisomerases.56 With that in mind, there are two known direct mechanisms for
topoisomerase inhibition. First is the formation of aforementioned cytotoxic
“topoisomerase poisons” that form ternary enzyme-DNA-inhibitor complexes and
prevent the rejoining of transiently cleaved DNA strands. The second mechanism is
catalytic inhibition via competition at the allosteric ATP site, or direct competition at the
active DNA site. As type IA topoisomerases act independently of ATP, any catalytic
inhibition would likely need to be accomplished by specifically targeting the DNA active
site. While the majority of published direct bacterial topoisomerase I inhibitors have been
shown to be “topoisomerase poisons,” scientific precedent does exist for catalytic
bacterial topoisomerase I inhibition via direct DNA competition.93,94 As such, this
research focuses on characterizing the DNA active site of SmTopoI as the first step in
rationally providing evidence of the possibility of selective topoisomerase I druggability.
Accordingly, a thorough structural understanding of the target enzyme is required to
identify key determinants of substrate and inhibitor binding along the DNA active site.
Such knowledge would support future efforts for the identification of novel chemical
probes and support the druggability of bacterial topoisomerase I. To gain such an
understanding, the structural determination of the enzyme at atomic resolution is
necessary. Substantial initial hurdles exist, however, as topo I is a DNA binding enzyme
and, as such, has been proven throughout the literature to be a highly difficult target
enzyme to purify and crystallize.95-97
Unfortunately, additional difficulties also exist that are unique to targeting topo I.
For example, unlike the ATP-dependent type IIA topoisomerases, the ATP-independent
type IA topoisomerases catalyze an energetically favorable event and rely solely on the
torsional strain of their DNA substrate to generate the energy required to carry out their
biological responsibilities relaxing hyper-negative supercoils or decatenating interlinked
DNA.55 This fact carries with it multiple liabilities. First, unlike the type IIA
topoisomerases, there is no opportunity to measure the expenditure of an energy source
when targeting type IA topoisomerases. As such, the only way to measure the activity of
the topo I enzyme, and in turn measure the inhibition of its activity, is by measuring the
degree of substrate DNA supercoiling that remains after incubation.
Aims
Protein Expression and Purification of SmTopoI
As mentioned above, inherent difficulties are involved with the purification of
DNA-binding proteins such as bacterial topoisomerase I. The initial need to separate
cellular DNA from the target enzyme introduces an early obstacle in the protocol. To
overcome such an obstacle, previous methods including treating extracts to batch anion
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exchange, DNase treatments, and DNA precipitations using different compounds like
streptomycin sulfate and polyethyleneimine have been employed.98 While each DNAseparation method has its own advantages and disadvantages, they all share a certain
degree of costliness with respect to time and resources. Previous studies regarding the
expression and purification of bacterial topoisomerase I have yielded varied results.
While truncated N-terminal fragments of E. coli topoisomerase I have been well studied
and characterized, the full-length enzyme is desirable for thorough characterization and
inhibitor development.99,100 In one study, the purification and analysis of full-length
topoisomerase I from the extremophile Thermotoga maritima was carried out (expressed
in E. coli with IPTG induction; heated to precipitate non-thermophile proteins and DNA;
purified using a heparin column followed by size exclusion chromatography) and yielded
2-3 mg/Liter.101,102 However, information gleaned from an extremophile would not
necessarily be expected to provide data that could be reliably applied to clinically
relevant bacteria. Another study detailed the purification of full-length topoisomerase I
from Streptococcus pneumonia (expressed in E. coli with IPTG induction followed by
dialysis, IMAC purification, and a second dialysis step), but did not report yield.93
Despite their noteworthy contributions to our understanding of bacterial topoisomerase I,
these studies either failed to report the amount of protein yielded from their respective
protocols, or the yield was relatively low, making biophysical and biochemical assay
studies logistically difficult. A study developing the purification of topoisomerase I from
E. coli yielded a significant amount of the enzyme, but would not be appropriate for
expressing and purifying topoisomerase I from non-E.coli bacteria as the protocol lacked
a method for separating non-native enzyme from native.103 More recent studies discussed
the purification of full-length E. coli and Mycobacterium tuberculosis topoisomerase I
used for the subsequent crystallization and characterization of the respective enzymes,
but did not report the yields.95,96
Herein, the expression, rapid two-step purification, and preliminary
characterization of full-length topo I from S. mutans with yields significantly greater than
previously reported purifications of bacterial topoisomerase I are reported. Notably, the
expression protocol requires significantly less effort than classical induction methods and
the purification protocol bypasses traditionally cumbersome DNA-removal methods and
can be carried out in a single day with an estimated purity of 95% or higher.
Structural Determination of SmTopoI_N65
As overall interest in type IA topoisomerases continues to increase, especially
with regard to efforts aimed at discovering and developing novel antibacterial agents—
particularly topo I inhibitors—the need for a greater amount of structural topo I data
becomes more apparent.56,57,93,97,104 Aiding in these efforts, several three-dimensional
apo- and co-crystal structures of topo I from various bacterial species have been
determined, including those from the gram-negative model organism E. coli (EcTopoI),96
the gram-negative extremophile Thermotoga maritima (TmTopoI),101 and the uniquely
non-gram-classified Mycobacterium tuberculosis (MtTopoI).95
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Though E. coli prevails as the predominant model organism in microbiological
research, inherent differences exist between gram-negative and gram-positive bacteria.
Accordingly, as Streptococcus mutans has gained utility as a gram-positive model
organism,105 efforts were undertaken to obtain diffraction-quality full-length S. mutans
topo I (SmTopoI) protein crystals. Though, similar to other topo I crystallization
campaigns reported in the literature, such efforts were met with initial difficulty.95,96
Therefore, rational constructs of main body N-terminal fragment of SmTopoI were
cloned and expressed to remove the flexible C-terminal domain and improve chances of
crystallization. This eventually led to a 65-kDa fragment (SmTopoI_N65) that yielded
high diffraction-quality crystals used for structural characterization of SmTopoI. Herein
the three-dimensional crystal structure of SmTopoI_N65, the first topo I structure
determined from a gram-positive bacterium and its corresponding structural
characterization are reported.
Materials and Methods
Reagents, Chemicals, Biologicals, and Equipment
Biological materials, equipment, and reagent-grade chemicals used were from the
following sources: Streptococcus mutans genomic DNA, ATCC® 700610D-5™ from
ATCC® (Manassas, VA); ArcticExpress(DE3) Competent Cells, pUC18 plasmid, XL1Blue Supercompetent cells, and BL21(DE3)-Gold Competent cells from Agilent
Technologies (Santa Clara, CA); ChampionTM pET SUMO Protein Expression System,
including One Shot® Mach1TM-T1R and BL21(DE3) One Shot® Chemically Competent
E. coli cells from invitrogenTM by Life TechnologiesTM (Carlsbad, CA); HyperLadder™
1kb Plus from Bioline USA Inc (Taunton, MA); pET-15b vector, pET-16b vector, and
pET-21d vector from Novagen® EMD Millipore® (Billerica, MA); Quick LigationTM
Kit, BamHI, NdeI, and NcoI restriction enzymes from New England Biolabs, Inc.
(Ipswich, MA); DifcoTM LB, Miller and Terrific Broth from BDTM (Franklin Lakes, NJ);
Thermo Scientific™ GelCode™ Blue Safe Protein Stain and SpectraTM Multicolor High
Range Protein Ladder from Thermo Fisher Scientific (Waltham, MA); HiMark™ Prestained Protein Standard, Novex™ InVision™ His-Tag In-Gel Stain, Platinum® PCR
SuperMix High Fidelity, NuPAGE® Novex® 3-8% Tris-Acetate Protein Gels, Novex™
NuPAGE™ LDS Sample Buffer (4X), and Novex™ NuPAGE™ Tris-Acetate SDS
Running Buffer and Molecular ProbesTM SYPROTM Orange Protein Gel Stain from
InvitrogenTM by Life TechnologiesTM (Carlsbad, CA); QIAGEN Plasmid Maxi Kit,
QIAquick PCR Purification Kit, and QIAprep Spin Miniprep Kit from Qiagen (Valencia,
CA); DTT, glycerol, IPTG, lysozyme, NaCl, MgCl2, protease inhibitor tablets (EDTAfree), Tris, Tris base, and Triton X-100 from Fisher Scientific (Pittsburgh, PA);DNase I
from Worthington Biochemical Corporation (Lakewood, NJ); ampicillin, kanamycin, and
KH2PO4 from Acros Organics, part of Thermo Fisher Scientific (Waltham, MA); 30,000
MWCO Amicon™ Ultra-15 Centrifugal Filter Units and Imidazole from EMD
Millipore® (Billerica, MA); K2HPO4 from Sigma Aldrich (St. Louis, MO); GelRed™
nucleic acid gel stain from Biotium, Inc. (Hayward, CA); primers synthesized by
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Integrated DNA Technologies (Coralville, IA); Hampton Solubility & Stability Screen
2TM from Hampton Research (Aliso Viejo, CA). ÄKTA Purifier FPLC, HisTrap-HP 5
mL column, and HiLoad 26/600 Superdex 200 PG size exclusion column from GE
Healthcare Life Sciences (Pittsburgh, PA).
Buffers
The mini-expression lysis buffer is composed of 75 uL of 1% n-octyl beta-Dthioglucopyranoside (OTG) in 20 mM Tris HCl (pH 7.5), 0.1 mg Lysozyme, 0.1 mg
DNase I, and 0.5 uL of 0.5 M MgCl2 for one cell pellet. The 2x LDS dye is composed of
5 mL Novex™ NuPAGE™ LDS Sample Buffer (4X), 500 mM DTT, and brought to 10
mL with ddH2O. The standard lysis buffer is composed of 20 mM sodium phosphate (pH
7.4), one Pierce® EDTA-free protease inhibitor tablet per 50 mL, 1 mM DTT, 0.5%
Triton X, 0.5 M NaCl, 5% glycerol, 0.5 mg/mL lysozyme, 5µg/mL DNase, and 5 mM
imidazole. Lysis buffer 2 is composed of standard lysis buffer without DNase I. Buffer
A is composed of 20 mM sodium phosphate (pH 7.4), 0.5 M NaCl, 5 mM imidazole, and
5% glycerol. Buffer B is composed of 20 mM sodium phosphate (pH 7.4), 0.15 M NaCl,
250 mM imidazole, and 5% glycerol. The size exclusion buffer is composed of 50 mM
sodium phosphate (pH 7.4) and 150 mM NaCl. Buffer C is composed of buffer A with
1M NaCl. Buffer D is composed of buffer B with 0.5M NaCl and 350 mM imidazole.
Size exclusion buffer 2 is composed of 20mM Tris (pH 8.0), 1 mM MgCl2, 0.5M NaCl,
and 1 mM DTT. The gel assay buffer and assay stop buffer were prepared as previously
reported.104 The gel assay buffer is composed of 10mM Tris pH 8.0, 50mM NaCl, and 6
mM MgCl2. The assay stop buffer is composed of 50mM EDTA, 50% glycerol, and
0.5% w/v bromophenol blue.
SmTopoI Cloning and Plasmid Construction
Initially, the topA gene was cloned from Streptococcus mutans UA159 genomic
DNA for insertion into the pET-15b vector based for the NdeI and BamHI restriction
sites using the following primers:
TopA_Forward: 5’-TGT AGA CAT ATG ACA AGT AAA ACA ACG ACA ACA-3’
TopA_Reverse: 5’-TCA TCA GGA TCC TTA TTT AAC AGC TTT TTC CTT-3’
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured
at 94 oC for 30 seconds, annealed at 58 oC for 40 seconds, and extended at 68 oC for two
minutes for 30 cycles and then held at 4 oC. Success was analyzed via 1% agarose gel
electrophoresis based upon the confirmed presence of the ~2Kbp SmTopA_pET PCR
product. SmTopA_pET was then purified using QIAQuick® PCR Purification Kit per
protocol. The pET-15b vector was then digested with NdeI and BamHI restriction
enzymes per New England Biolabs (NEB) protocol, purified, then mixed and ligated with
the SmTopA_pET PCR product via NEB Quick LigationTM Kit protocol. The ligation

31

product (SmTopA15b) was then transformed into XL1-Blue Supercompetent cells per
protocol. Upon successful transformation, the plasmid was isolated with the QIAprep
Spin Miniprep Kit via protocol and the sequence was confirmed via Retrogen, Inc. (San
Diego, CA). The plasmid was also transformed into BL21(DE3)-Gold Competent cells
via protocol.
The topA gene was sub-cloned from the pET-15b vector in XL-1 Blue into the
pET-16b vector using NdeI and BamHI restriction enzymes and NEB Quick Ligation TM
Kit per manufacturer protocols.
For the pET 21d vector, the SmTopA gene was amplified via PCR around NcoI
and BamHI restriction sites using the following primers:
NcoI_Site_For: TAT ACG ATG GGC AGC AGC CAT CAT C
NdeI_Site_For: GGC AGC CCC ATG GCA AGT AAA AC
BamHI_Site_Rev: TTC GGA TCC TTT TTA ACA GCT TTT TCC TTA TAG TCA
CAC
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured
at 94oC for 30 seconds, annealed at 58oC for 45 seconds, and extended at 68oC for two
minutes and thirty seconds for 35 cycles and then held at 4 oC.
For the pET-SUMO vector, the topA gene was cloned from PCR with “hanging
T” ends per ChampionTM pET SUMO Protein Expression System protocol using the
following primers:
TopA_SUMO_For: AGC ACA AGT AAA ACA ACG ACA ACA GTA AAA AAG
ACG
TopA_SUMO_Rev: TTA TTT AAC AGC TTT TTC CTT ATA GTC ACA CTC
CTT ATT GC
PCR was carried out via Platinum® PCR SuperMix High Fidelity protocol and denatured
at 94oC for 30 seconds, annealed at 60oC for 45 seconds, and extended at 68oC for two
minutes and thirty seconds for 35 cycles and then held at 4 oC.
All gene and respective plasmids were ligated and transformed per respective
protocols per respective protocols into XL1-Blue Supercompetent cells and BL21(DE3)Gold Competent cells except the SmTopA_SUMO plasmid used with the ChampionTM
pET SUMO Protein Expression System, which utilized included One Shot® Mach1TMT1R and BL21(DE3) One Shot® Chemically Competent E. coli cells. Sequences were
confirmed by sequencing via Retrogen, Inc. (San Diego, CA).
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Mini-Expression of SmTopI15b
A mini-expression was initially conducted in order to determine preliminary
expression conditions, starting with a 5-mL LB and 100 ug/mL starter culture of
SmTopI15b in BL21(DE3)-Gold grown at 32oC overnight. Upon the next day, the sample
was diluted 100-fold into three 5-mL sterile TB and 100 ug/mL ampicillin samples for
each of three different temperatures: 37oC, 25oC, and 18oC. Cultures were then grown for
two hours, then one sample from each temperature was induced with 1 mM IPTG, one
with 0.5 mM IPTG, and one remained un-induced. Samples were then grown an
additional twenty-four hours, then centrifuged at 10,000 rpm for five minutes. The
supernatant was then removed and each pellet was dissolved in Mini_Lysis_Buffer for
five minutes. Cells were re-suspended and vortexed for 30 seconds to completely
dissolve and the samples were centrifuged at 13,000 rpm for five minutes. The
supernatants were then separated into clean 1.5 mL microcentrifuge tubes as the soluble
fractions. Pellets were washed by re-suspending in 30 uL of 1% OTG in 20 mM Tris (pH
7.5) and centrifuging at 13,000 rpm for five minutes. The supernatant was then discarded.
Pellets were once again re-suspended in 30 uL of 1% OTG in 20 mM Tris (pH 7.5) and
mixed with 30 uL of LDS_Sample_Buffer, then centrifuged again at 13,000 rpm for five
minutes with the resulting supernatant containing the insoluble fraction. 10 uL samples
were then heated at 95oC for five minutes and loaded on SDS-PAGE gels for analysis.
Mini-expression was repeated for 48-hour growths as well. (Data not shown.) Miniexpression was again repeated with SmTopI16b at 18oC.
Expression of SmTopoI constructs and cell lysis
Expression and purification experiments were conducted in duplicate. SmTopI15b
initial starter cultures were grown in BL21 cell lines at 32°C overnight in 5-mL LB with
100 ug/mL ampicillin (pET constructs) or 50 ug/mL kanamycin (SUMO construct) and
used to inoculate 500mL TB with respective antibiotics. Cultures were grown to OD600
~0.6, induced with 0.5 mM IPTG, and expressed at 18°C for 24 hours. Auto-induction
was carried out per Studier protocol with SmTopI16b and grown for 24 hours at 37°C.106
All samples were then centrifuged at 15,000 g for 30 minutes at 4oC and the supernatants
were discarded. Pellets were stored at -80oC.
Cell pellets for all constructs were thawed at room temperature and immediately
lysed in the standard lysis buffer by stirring for 1 hour at 4°C. Samples were then
sonicated for 8 minutes, centrifuged at 18K rpm at 4°C for 15 minutes, filtered at 0.22
um, and collected. Auto-induction samples were lysed in the same fashion, except lysis
buffer 2 was used, and then samples were sonicated and filtered as above.
Purification of SmTopoI constructs
Each initial construct sample was purified using a HisTrap-HP 5 mL column on
an ÄKTA Purifier FPLC. Samples were loaded at 1 mL/min, washed with 20 column
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volumes (CVs) Buffer A at 2.5 mL/min, and eluted via linear gradient from 100% Buffer
A to 100% Buffer B over 20 CVs at 2.5 mL/min. Samples were then collected and
concentrated using a 30,000 MWCO Amicon™ Ultra-15 Centrifugal Filter Unit. The
SmTopI16b sample was collected and loaded onto a GE HiLoad 26/600 Superdex 200
PG size exclusion column and eluted with 1.5 CV of SE Buffer. The sample expressed
via auto-induction (SmTopI16b_AI) was purified similarly, except it was loaded and
washed with Buffer C for 40 CVs and eluted with a step gradient of Buffer D using 7CV
steps at 15%, 20%, and 100% with the sample eluting in a sharp peak in the 100% step.
The sample was then loaded onto a pre-equilibrated GE HiLoad 26/600 Superdex 200 PG
size exclusion column and eluted with SE Buffer 2. All sample concentrations were
attained via Bradford assay with BSA as the standard.
Biochemical Assays
Gel assays were used to confirm target protein activity using published
methods.104 The pUC18 plasmid was isolated via QIAGEN Plasmid Maxi Kit per
protocol. Enzyme assays were conducted in standard volumes of 20µL comprised of 25,
50, 75, 100, 150, 200, or 400 ng SmTopI; 500 ng negatively supercoiled pUC18 plasmid;
and a sufficient quantity of gel assay buffer to bring the reaction volume to 20 uL. One
unit of commercially obtained E. coli topoisomerase I was substituted for SmTopI as a
positive control. Assays were incubated at 37⁰C for 30 minutes and then terminated using
5µL of assay stop buffer per reaction. DNA relaxation activity was monitored on 0.7%
agarose gels in Tris-Acetate-EDTA TAE buffer at 20V for 10 hours and then stained with
GelRed™ nucleic acid gel stain per protocol. Freeze trials were conducted similarly using
1 ug (high concentration) or 400 ng (low concentration) of enzyme in 50% glycerol or
0% glycerol and either snap-frozen in liquid nitrogen, frozen drop-wise in liquid nitrogen
and stored at -80oC overnight, or simply refrigerated. Non-specific DNAse activity assay
was conducted using published methods and incubated for 6 hours.103
Thermal Stability Assay
Protein stability and solubility conditions were analyzed via the use of Hampton
Research Solubility and Stability Screen 2TM per protocol to evaluate buffers and salt.
Peptide fingerprinting
Target protein identity was confirmed by standard in-gel tryptic digest and LCMS analysis.107-109 Peptide spectra matching and protein identification was achieved by
database search using Sequest HT algorithm in Proteome Discoverer 1.4 (Thermo
Scientific).
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SmTopoI Protein Homology Modeling
A homology model of the SmTopoI protein (Figure 2-1) was built using the E.
coli 67-kDa N-term fragment (1ECL) and T. maritima (2GAI) topoisomerase I crystal
structures as templates, the Streptococcus mutans (UA159 strain) protein sequence, and
the program MODELLER.110,111
SmTopoI_N65 Cloning, Expression, Purification and Crystallization
SmTopoI_N65 was cloned, expressed, and purified to over 95% purity via PAGE
analysis similarly to full-length SmTopoI described elsewhere.73,74 However, the target
construct gene of interest, topA_N65, was amplified via PCR off of the topA-containing
SmTopI_16b plasmid from above based around the NdeI and BamHI restriction sites
using the following primers:
TopA_Forward: 5′-TGT AGA CAT ATG ACA AGT AAA ACA ACG ACA ACA
G-3′
TopA_N65_Rev: 5’-GGA TGG ATC CTT ACT GTT CCT CTG C-3’
The gene was ligated into a pET-15b vector (Novagen® EMD Millipore®,
Billerica, MA) and the target plasmid was transformed into BL21(DE3)-Gold Competent
cells (Agilent Technologies, Santa Clara, CA) per the manufacturer’s specified protocol.
The target enzyme was expressed via auto induction and purified per previous protocol,
except Tris was substituted for all phosphate buffers.73,106 Briefly, cells were lysed for 1
hour at 4°C in Lysis Buffer composed of 20 mM Tris-hydrochloride (HCl) pH 8.0, one
Pierce® EDTA-free protease inhibitor tablet per 50 mL, 1 mM DTT, 0.5% Triton X, 0.5
M NaCl, 5% glycerol, 0.5 mg/mL lysozyme, and 5 mM imidazole, then sonicated,
centrifuged, and filtered at 0.22 m. Hexa-his-tagged protein was purified using a
HisTrap-HP 5 mL column on an ÄKTA Purifier FPLC (GE Healthcare Lifesciences,
Pittsburgh, PA) via step-gradient nickel immobilized metal affinity chromatography
(IMAC) in Buffer A, composed of 20 mM Tris-HCl pH 8.0, 1 M NaCl, 5 mM imidazole,
and 5% glycerol, and Buffer B, composed of 20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 350
mM imidazole, and 5% glycerol. The sample was then purified on a GE HiLoad 26/600
Superdex 200 PG size exclusion chromatography (SEC) column in SEC Buffer,
composed of 20 mM Tris (pH 8.0), 1 mM MgCl2, 0.5 M NaCl, and 1 mM DTT. Target
protein fractions were pooled, concentrated with a 10,000 MWCO AmiconTM Ultra-15
Centrifugal Filter Unit from EMD Millipore® (Billerica, MA) and used for
crystallography.
SmTopoI_N65 was crystallized at 4.6 mg mL-1 in a 3uL:3uL 1:1 ratio protein to
condition using the hanging-drop vapor-diffusion method off of a coarse-matrix screen.
The initial crystal growth condition was JCSG-plus (Molecular Dimensions, Maumee,
OH) condition 1-5 (0.2 M magnesium formate dihydrate, 20% w/v PEG 3350) at 18°C. A
1:1 mixture of Izit Crystal Dye (Hampton Research, Aliso Viejo, CA) and acid red dye
was added to original crystal-containing drops and allowed to stain overnight for
preliminary crystal assessment. Unstained crystals from the same well, but from a
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different drop, were collected for X-ray diffraction analysis. Initial crystals showed
relatively weak diffraction (greater than 4 Å). Optimized crystals were then obtained via
fine grid screen in 0.2 M magnesium formate dihydrate, 25% w/v PEG 3350 at 4°C and
unstained crystals were collected for analysis. Crystals were grown in 48-well VDX
plates with sealant (Hampton Research, Aliso Viejo, CA) and were visible within two
weeks.
SmTopoI_N65 Structure Determination and Refinement
SmTopoI_N65 crystals were harvested, looped through 20% w/v PEG 3350/30%
MPD in the crystallization condition for cryo-protection, and cooled to 100 K for data
collection. A complete data set was collected at GM/CA-CAT beamline 23ID-D of sector
23 of the Advanced Photon Source (APS), Argonne National Laboratory, Lemont,
Illinois, USA (Table 2-5). Data were processed and scaled, then the structure of
SmTopoI_N65 was determined via molecular replacement using the previously
determined 67-kDa N-terminal fragment of EcTopoI (PDB 1ECL)100 all using the HKL3000 suite.112 Initial automatic model building was performed within HKL-3000 using
Buccaneer.112,113 Refinement was then conducted using phenix.refine and the model was
further built out using AutoBuild from the PHENIX suite.114 Subsequent refinement and
model building was conducted iteratively with phenix.refine and Coot.114,115 Late-stage
automated re-refinement was conducted using PDB_REDO.116 Validation of the structure
was conducted within PHENIX using MolProbity.117 Figure 2-14 was produced with the
UCSF Chimera package.118
TopoI Sequence and Structure Alignments
SmTopoI_N65, EcTopoI_N67, EcTopoIII (PDB 1D6M), and MtTopoI sequence
alignment was generated with the ESPript 3 server (http://espript.ibcp.fr/) using a
multiple protein sequence alignment produced with Clustal Omega, with secondary
structure information extracted from the SmTopoI_N65 structure.119,120 Residues within
5Å of the active site Y316 were determined with UCSF Chimera and the structure
distances measurement tool.118 Structural alignment of SmTopoI_N65 with
EcTopoI_N67 (PDB 1ECL) and MtTopoI (PDB 5UJ1) conducted with UCSF Chimera
MatchMaker structure comparison tool.100,101,118
Generation of SmTopoI_N65 Topology Model
The SmTopoI_N65 topology model was generated with PDBsum and SmTopoI_N65.pdb
structure file.121
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SmTopoI_N65 Multiple Sequence Alignment with Select Topo I Homologs of
Undetermined Structure
SmTopoI_N65, EcTopoI_N67, and MtTopoI sequence alignment was generated
similarly as done described in the main manuscript with the ESPript 3 server
(http://espript.ibcp.fr) using a multiple protein sequence alignment produced with Clustal
Omega, with secondary structure information extracted from the SmTopoI_N65
structure.119,120 Residues within 5Å of the active site Y316 were determined with UCSF
Chimera and the structure distances measurement tool.118
Structural Alignment of SmTopoI_N65 and TmTopoI (PDB 2GUI)
Structural alignment of SmTopoI_N65 with TmTopoI (PDB 2GUI) conducted
with UCSF Chimera MatchMaker structure comparison tool.101,118 The unique loop
extension near the active site of SmTopoI_N65 is highlighted with a red circle.
SmTopoI_N65 Sequence Alignment with EcTopoIII (PDB 1D6M)
SmTopoI_N65 and EcTopoIII (PDB 1D6M) sequence alignment figure was
generated with ESPript 3 server (http://espript.ibcp.fr) using multiple protein
sequence alignment from Clustal Omega and secondary structure information from
SmTopoI_N65 structure.119,122
Results
Cloning and Expression of Recombinant SmTopoI
Considering the need to rapidly isolate SmTopoI from host E. coli topoisomerase
I, cloning into a poly-histidine affinity tag system was chosen and implemented. The S.
mutans topA gene was first cloned and inserted into the pET15b vector (SmTopA15b),
introducing a hexa-Histidine (hexa-His) tag at the N-terminus of the target enzyme.123
The target gene was also cloned or sub-cloned into several alternate vectors in order to
analyze the effects of different constructs, including affinity tag location and size, as well
as the usefulness of a protein fusion tag. BL21(DE3)-Gold Competent cells were used for
the over-expression of target protein. The target gene was also transformed into the
ArcticExpress Competent Cell system to evaluate the utility of expressing at lower
temperatures (12oC) in order to increase solubility, but was not found to significantly
improve results in this instance (data not shown).124,125
Preliminary mini-expression results from the SmTopI15b construct led to a
traditional IPTG induction and expression that was implemented across all constructs in
duplicate. Expression products were then carried into initial IMAC nickel column
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purification trials using a standard linear imidazole elution protocol. While SmTopI16b
from the N-term deca-His construct and SmTopI-SUMO both significantly outperformed
the others, SmTopI16b was ultimately selected and carried forward (Table 2-3). Of note,
as the SmTopI-SUMO enzyme approached the customary 100-kDa E. coli expression
cutoff, the additional 11 kDa in size added by the SUMO fusion tag showed no apparent
deleterious effect on the expression in this respective system, demonstrated by the
average calculated amounts of expressed recombinant protein from the construct trials
resulting in 88.9 pmol for the ~83 kDa SmTopI16b and 100 pmol for the ~93 kDa
SmTopI-SUMO, respectively.
As further loss of target protein was anticipated with additional purification steps,
different conditions were also employed in order to further increase target protein
expression and convenience, including the implementation of auto-induction for protein
expression.106 Upon transitioning from a classical IPTG-induction method to a standard
auto-induction method, the yield of SmTopI16b increased dramatically, as did the
convenience of the protocol (Table 2-3).106 A subsequent IPTG mini-expression profile
of SmTopI16b was also conducted in order to determine favorable IPTG expression
conditions, which was also compared to auto-induced expression and illustrated no
apparent loss of solubility from adopting an auto-induction method (Figure 2-2).
Purification of Recombinant SmTopoI
Early exploratory nickel-nitrilotriacetic acid (Ni2+-NTA) column IMAC
purification with the pET15b N-term hexa-His tag system showed the affinity of the
tagged target protein for the Ni2+-NTA column to be markedly weak, leading to both an
unacceptable loss of target protein during wash steps and very early dissociation upon
elution. Furthermore, it was discovered upon peptide fingerprinting analysis that what
was initially presumed to be the ~83 kDa SmTopI15b target protein upon SDS-PAGE
analysis was actually the ~84 kDa native E. coli catalase HPII protein co-eluting with the
target protein (Figure 2-3).
Comparative analysis of chromatographic linear elution profiles from the
SmTopoI IMAC purification trials showed a slight increase in the retention time for the
deca-His tagged target protein relative to the hexa-His tags (Figure 2-4). Therefore, the
precise point of elution of SmTopI16b from the linear gradient was observed to be at
25% elution buffer (about 90 mM imidazole), and this aspect was used to develop a step
elution protocol. Upon implementation of a 15%, 20%, 100% step elution protocol,
SmTopI16b eluted in a sharp peak at the 100% elution step and was successfully
separated from contaminating proteins, including E. coli catalase HPII, as determined by
SDS-PAGE analysis and His-staining (Figure 2-3). As such, the pET16b N-term decaHis tag system was deemed the most successful and carried forward for further
experimentation.
While analyzing mini-expression data, it was determined that target protein
solubility could likely be improved. A simple transition from 50 mM Tris-HCl pH 8.0 to
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Table 2-3.
constructs.

Comparative summary of purification yields from SmTopoI

Vector
System
pET-15b

System
Characteristics
N-term 6X His tag

pET-16b

N-term 10X His tag

pET-21d

C-term 6X His tag

SUMO
pET-16b

N-term SUMO fusion
tag and N-term 6X His
tag
N-term 10X His tag

pET-16b

N-term 10X His tag

Growth/Induction Method
500 mL TB; 0.5 mM IPTG;
18oC x 24 h
500 mL TB; 0.5 mM IPTG;
18oC x 24 h
500 mL TB; 0.5 mM IPTG;
18oC x 24 h
500 mL TB; 0.5 mM IPTG;
18oC x 24 h

Overall Yield
(mg/500 mL)a
4.94 (IMAC)
7.11 (IMAC)
6.24 (SE)
4.11 (IMAC)
9.12 (IMAC)

500 mL TB; 0.5 mM IPTG;
8.30 (IMAC)
18oC x 24 h; high salt
500 mL auto-induction media; 14.21 (IMAC)
37oC x 24 h; high salt
11.66 (SE)

a

Overall yields are an average of two 500 mL growths in respective media.
Reprinted from final submission with permission from Elsevier Inc. Jones, J. A., Price,
E., Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://doi.org/10.1016/j.pep.2016.04.010 (2016).73
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Figure 2-2.

Mini-expression SDS-PAGE.

Mini-expression of SmTopI16b comparing 0.5 mM and 1 mM IPTG induction at 18oC
over different times as well as auto-induction at 37oC over 24 hours (Sol, soluble
fraction; Ins, insoluble fraction; AI, auto-induction). Insoluble auto-induction fraction not
shown as it repeatedly resulted in an unacceptably high amount of smearing, presumed to
be due to substantial pellet size and an excess of cellular debris.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010 (2016).73
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Figure 2-3.

Catalase contaminant SDS PAGE.

SDS-PAGE showing initial difficulty presented by native catalase HPII contaminant at
~84 kDa and target enzyme at ~83 kDa during purification of N-term hexa-His-tagged
SmTopI_15b construct. Lane 1, ladder; 2-4, nickel column flow-through; 5-7, early
nickel elution peak; 8-9, middle nickel elution peak; 10-12, tail end shoulder of nickel
elution peak.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010 (2016).73
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Figure 2-4. Chromatogram of nickel column linear elution from preliminary
construct trials.
Direct vertical comparison. (A) N-term hexa-His-tagged SmTopI_15b construct. (B) Nterm deca-His-tagged SmTopI_16b construct. (C) C-term hexa-His-tagged SmTopI_21d
construct. (D) N-term SUMO and hexa- his-tagged SUMO construct.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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20 mM phosphate buffer pH 7.4 in the lysis and nickel column buffers showed an
apparent increase in yield and increasing the ionic strength of the nickel column binding
and wash buffers (from 150 mM to 1 M NaCl) and the nickel column elution buffer (from
150 mM to 500 mM NaCl) greatly increased the overall purification yield of SmTopI16b
(Table 2-3 and Figure 2-5). A long wash step over 40 CVs with the higher ionic strength
binding buffer also resulted in satisfactory removal of DNA from the target protein.
Absorbance at 260 nm and 280 nm was monitored, ensuring the maximal removal of
DNA. As stated above, transitioning to an auto-induction expression protocol also
significantly improved yield and convenience.
Following successful IMAC purification, SmTopI16b was identified upon SDSPAGE analysis as an overexpressed band (Figure 2-5a). Target protein identity was
confirmed initially using mass spectrometry peptide fingerprinting (Figure 2-6),
secondarily upon His-epitope tag antibody directed western blot (data not shown), and
again using His-tag staining (Figure 2-5b). Protein concentrations and yield were
calculated using the standard Bradford protein assay with BSA as the protein standard,
which is compatible with the IMAC elution buffer.126
Following optimization of the IMAC purification step, analyses with several
alternative secondary purification methods, including the use of a heparin column, cation
and anion exchange columns, a Cibacron Blue column, and a size exclusion (SE) column
were conducted. Ultimately, transitioning straight from IMAC to a second, polishing size
exclusion step was chosen due to simplicity and the fact that it showed the overall
greatest yield. The target protein size of ~83 kDa was judged to be distinct enough from
any of the remaining ~97 kDa native E. coli topoisomerase I to separate them using size
exclusion chromatography. After increasing the ionic strength of the size exclusion buffer
(from 150 mM NaCl to 500 mM NaCl), the target protein solubility was found to be
sufficient for purification without the need for an intermediate buffer exchange or dialysis
step of the Ni2+-NTA purification product, which again afforded an additional gain in
speed and convenience. Following the size exclusion chromatography polishing step, the
target protein was collected and again analyzed via SDS-PAGE, indicating purity deemed
greater than 95%. Yield was again determined from duplicate trials by Bradford protein
assay with BSA as a standard, which indicated over 23 mg/L of target protein (Table 2-3
and Table 2-4).
Characterization of SmTopoI
In order to track protein activity, a gel-based DNA-relaxation assay was employed
using published methods (Figure 2-7).104 The activity of SmTopI16b was maintained
over three months in SE Buffer 2 refrigerated at 4oC, as well as after overnight freeze
trials at -80oC including enzyme with and without 50% glycerol using both snap-freezing
and drop-wise freezing methods in liquid nitrogen (Figure 2-8). Protein activity after
cleavage of the deca-His tag was also analyzed, showing no apparent increase in activity
(Figure 2-9). Furthermore, the absence of DNase activity was determined via the
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Figure 2-5.

SDS-PAGE gels of SmTopI_16b purification results.

(A) SDS-PAGE after blue-staining. (B) SDS-PAGE after His-staining in order to verify
target protein bands. L, ladder; CE, clarified extract from auto-induction growth; FT,
nickel column flow-through; P1, nickel column first peak from first step elution using
high salt buffers; Ni2+, target fraction from nickel column; SE, target fraction from size
exclusion; Ec; commercially available E. coli topoisomerase I; TB, target fraction from
nickel column from TB growth with high salt buffers.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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Figure 2-6.

Peptide fingerprinting.

Peptide fingerprinting analysis showing 74.20% sequence coverage for Topoisomerase I
from Streptococcus mutans serotype c (strain ATCC 700610/UA159).
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73

Table 2-4.
Step
Clarified
extract
Nickel
column
Size
exclusion
column

Summary of S. mutans topoisomerase I purification.
Total
Protein
(mg)a
1445

Target
Protein
(mg)b
107.3

Total
Activity
(units)c
N/A

Specific
Activity
(units/mg)
N/A

28.4

25.3

N/A

23.3

22.6

58,250

a

Yield Purity
(%)
(%)d
100

7.4

N/A

24

89

2,575

21

97

Protein concentration determined by Bradford assay using BSA as the standard protein.
Amount of target protein determined based off of SDS-PAGE gel analysis.
c
Activity measured as described under Materials and Methods section.
d
Purity determined based off of SDS-PAGE gel analysis.
Reprinted from final submission with permission from Elsevier Inc. Jones, J. A., Price,
E., Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://doi/org.10.1016/j.pep.2016.04.010 (2016).73
b
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Figure 2-7.

Gel-based DNA relaxation assay.

Lane 1, ladder; lane 2, supercoiled pUC18 plasmid (DNA substrate as negative control);
lane 3, commercially available E. coli topoisomerase I (positive control); lanes 4-10,
SmTopI16b enzyme in increasing concentration (nM). N, nicked; FR, fully relaxed; PR,
partially relaxed; SC, supercoiled.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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Figure 2-8.

SmTopI16b freeze trials.

Agarose gel showing activity of target enzyme frozen via different methods (1 ug enzyme
used, except 400ng used for [low] samples and 1 unit for EcTopoI positive control).
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73

Figure 2-9. His-tag cleavage activity assay.
Agarose gel showing activity of SmTopI16b after cleavage of deca-his tag via factor Xa.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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implementation of a non-specific DNase activity assay using published methods (Figure
2-10).103
To characterize the stability of SmTopI16b, a number of methods were employed.
Hampton Research Solubility & Stability Screen 2™ was used to assess conditions that
mitigate target protein precipitation and increase its overall stability.127 Optimal buffer
conditions as determined via Differential Scanning Fluorimetry (DSF, or “thermal shift”)
from the screen were found to be 0.05 M sodium citrate tribasic dihydrate (pH 5.0) with
4.0 M sodium chloride as showcased by an optimal melting temperature (Tm) of 48oC
(Figure 2-11). An apparent trend was seen showing optimal buffer conditions included
relatively low pH and high salt content. Protein solubility was also analyzed via overnight
dialysis trials into lower-salt-containing buffers across a wide range of pH values. Results
showed considerable visual precipitation regardless of buffer and pH when ionic strength
was decreased below 200 mM NaCl with protein concentration at 1 mg/mL, indicating
the necessity of a higher ionic strength buffer for the solubility of this particular enzyme
and construct (data not shown).
Crystallization of SmTopoI_N65
As reported previously, soluble full-length SmTopoI did not initially express well
and, even after expression was optimized, its solubility required extremely high salt
conditions not generally conducive to crystallization.73 As such, full-length SmTopoI
proved recalcitrant to crystallization. Eventually, the C-terminal domain was rationally
removed for subsequent crystallization trials. Iteratively shorter N-terminal fragment
SmTopoI constructs corresponding to the original 67-kDa N-terminal EcTopoI
(EcTopoI_N67) crystal structure (PDB 1ECL)99,100 were cloned, expressed, purified, and
screened for crystals. After multiple fragments were screened, this eventually proved
successful as diffraction-quality crystals of the 65-kDa 575 residue SmTopoI fragment
were attained, however the diffraction resolution was relatively low (greater than 4 Å).
Upon fine grid screening and implementation of temperature trials, high-resolution
quality crystals were grown (Figure 2-12), and the structure was determined (PDB
6OZW).
Overall Structure of SmTopoI_N65
The three-dimensional crystal structure of SmTopoI_N65 was determined to 2.06
Å via molecular replacement using the EcTopoI_N67 crystal structure (PDB 1ECL) as a
model,99,100 followed by iterative cycles of model building and refinement (Table 2-5). A
sequence alignment between SmTopoI_N65 and EcTopoI_N67, which share a 42.9%
sequence identity, is shown (Figure 2-13). The root mean square deviation (RMSD)
between the two structures is 1.83Å. Analysis of the crystal structure and Matthews
Coefficient indicate that there is one monomeric SmTopoI_N65 molecule per asymmetric
unit (Figure 2-14).128-130 The monomeric state of SmTopoI_N65 was further
corroborated by PISA (Protein, Interface, Structures, and Assemblies) analysis.131
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Figure 2-10. Non-Specific DNase Activity Assay.
Agarose gel confirming a lack of DNase activity after 6 hours incubation.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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Figure 2-11. Thermal stability data.
Data showing differing thermal stability profiles of SmTopI16b with different salts and
buffers.
Reprinted from final submission with permission of Elsevier Inc. Jones, J. A., Price, E.,
Miller, D. & Hevener, K. E. A simplified protocol for high-yield expression and
purification of bacterial topoisomerase I. Protein Expr Purif 124, 32-40,
https://dx.doi.org/10.1016%2Fj.pep.2016.04.010. (2016).73
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Figure 2-12

SmTopoI_N65 crystals.

A. Original SmTopoI_N65 crystals grown at 18°C from coarse JCSG plus screen,
condition 1-5 (0.2 M magnesium formate dihydrate and 20% PEG 3350). B. Same crystal
as in (A), but stained with a 1:1 mixture of Izit Crystal Dye (Hampton Research, Aliso
Viejo, CA) and acid red dye. C. Optimized SmTopoI_N65 crystal grown in 0.2 M
magnesium formate dihydrate and 25% PEG 3350 at 4°C used for structure
determination.
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Table 2-5.

Data collection and refinement statistics for SmTopo_N65.

Data Collection
Wavelength (Å)
Space Group
Unit cell parameters
a, b, c (Å)
, ,  (°)
Resolution (Å)
CC1/2
Rmeas
Rpim
Total no. of reflections
No. of unique reflections
Completeness (%)
Redundancy
Mean I/sigma
Refinement
Number of reflections used
Resolution (Å)
Rwork
Rfree
No. of non-H atoms
Macromolecules
Ligands
Solvent
Protein residues
RMS (bonds)
RMS (angles)
Ramachandran favored (%)
Ramachandran allowed (%)
Ramachandran outliers (%)
Rotamer outliers (%)
Clash score
Average B-factor
Macromolecules
Ligands
Solvent

Results
1.033
P 21 21 2
88.58 98.37 72.71
90 90 90
50.00 - 2.06 (2.10 - 2.06)a
0.999 (0.690)
0.084 (1.047)
0.032 (0.441)
254919
32714 (1394)
82.17 (35.50)
6.5 (5.1)
21.8 (1.5)
32713 (1395)
49.18 - 2.063 (2.137 - 2.063)
0.2003 (0.2310)
0.2677 (0.3617)
4700
4339
48
313
538
0.008
0.92
96.24
3.20
0.56
0.42
4.98
33.18
33.10
45.88
32.35

a

Statistics for the highest-resolution shell are shown in parentheses.
CC1/2 is the Pearson’s correlation coefficient of random half sets of data.
Adapted from final submission with open access permission from Elsevier Inc. Jones, J.
A. & Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of
DNA topoisomerase I from the gram-positive model organism Streptococcus mutans.
Biochem Biophys Res Commun, https://doi/org.10.1016/j.bbrc.2019.06.034 (2019. In
Press).74
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Figure 2-13. Multiple sequence alignment of SmTopoI_N65 and structural
homologs.
Comparison of SmTopoI_N65, EcTopoI_N67, and MtTopoI via multiple sequence
alignment shows high degree of sequence identity and similarity, including the highly
conserved active site. Identical residues are highlighted in red, similar residues are
highlighted in yellow, catalytic tyrosine is indicated with a red dot, active site residues
within 5 Å from catalytic tyrosine are indicated with blue dots, and the nine-residue loop
extension seen in SmTopoI_N65 is indicated with a magenta bar.98,99,118
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Figure 2-14. Overall structure of SmTopoI_N65
A. Flat ribbon diagram of the overall structure of SmTopoI_N65 showcasing the four Nterminal domains that comprise the main body. D1, D2, D3, and D4 are colored in blue,
orange, yellow, and green, respectively. Sub-domain secondary structures are also
numbered respectively. The unique loop extension before and immediately adjacent to
the active site in D3 between α2 and α3 is colored magenta. The small outcropping from
D1 that is considered a part of D4 as in the EcTopoI and MtTopoI structures is colored
charcoal. The catalytic Y316 residue in D3 is drawn in stick and colored red. B. Mesh
surface diagram of SmTopoI_N65 with the same color and orientation as in A, but turned
on x axis by -10° for improved view of DNA binding site and groove, shown as a red
arrow, with accompanying 90° turn along the y axis for profile view. C. Coulombic
surface coloring showing electrostatic potential with standard red/negative and
blue/positive coloring in the same orientation as B. The DNA binding site and groove is
also shown with a red arrow. D. Structural alignment of SmTopoI_N65 with
EcTopoI_N67 (1ECL) and MtTopoI.118
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Electron density of the hexa-histidine tag is not visible in the model, nor is density for the
first leading 18 N-terminal residue peptide chain (M1 to T18), which exists as an
additional N-term extension compared to EcTopoI, similar to the first 16 residues seen in
MtTopoI (PDB 5UJ1).95 This unmodeled N-term peptide continues to be of unknown
function. It carries substantial positive charge and is relatively polar, with five positively
charged lysines and one positively charged arginine, as well as six polar uncharged
threonines and two polar uncharged serines. The SmTopoI_N65 model begins at P19,
with K21 of SmTopoI_N65 aligning with K3 of EcTopoI_N67. This represents the
beginning of the highly conserved topoisomerase-primase (TOPRIM) domain, which
ends at N129 and N140 of SmTopoI_N65 and EcTopoI_N67, respectively.132
The SmTopoI_N65 model includes the first four domains of the overall structure,
which comprise the main body core and show an intricate topology (Figure 2-14 and
Figure 2-15).133 Domains D1, D3, and D4 form the base of the body, and D2 forms the
bulk of the toroid arch that represents the hinge domain. D1 is comprised of four alpha
helices and three beta strands. D2 is connected to D4 via a bridge of two flexible loops
and is comprised overall of two alpha helices and six beta strands. D3 is comprised of
five alpha helices, with a likelihood of α4 actually forming a 310 helix. The catalytic
Y316 residue is also located within D3 on a loop between α2 and α3 at the interface of
D1, D3, and D4. The remainder of the highly conserved active site surrounds the catalytic
tyrosine residue.
While the SmTopoI_N65 fragment shares 42.9% sequence identity with the
EcTopoI_N67 sequence and 25.19% sequence identity with the EcTopoIII sequence
(PDB 1D6M, Figure 2-16), full-length SmTopoI shares 41.4% identity with full-length
EcTopoI and 25.3% with full-length E. coli topo III, 37.1% identity with full-length
MtTopoI, and 42.8% identity with full-length topo I from the thermophile T. maritima
(TmTopoI).120 Of note, full-length SmTopoI shares 61.9% identity with the topo I
enzyme from Staphylococcus aureus (SaTopoI), for which there is currently no
determined three-dimensional structure.
Discussion
Expression and Purification of SmTopoI
An active full-length bacterial topoisomerase I enzyme has been purified to a
relatively high yield and purity from the clinically relevant bacteria S. mutans. A
systematic analysis of different protein constructs was necessary as an unacceptable
amount of the prototype hexa-his tagged protein showed weak affinity for the nickel
column and was therefore lost to flow-through and overly contaminated with early coeluting proteins. In order to analyze the possibility of the obstruction of the N-term His
tag in the protein’s folded state, the target gene was cloned into a pET21d vector
(SmTopA21d), placing a hexa-His tag at the C-terminus. As increasing the length of
histidine tags has been shown to increase affinity to Ni2+-NTA, allowing for the use of
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Figure 2-15. SmTopoI_N65 topology diagram.
Topology diagram of SmTopoI_N65 created with PDBsum showing beta strands as pink
arrows and alpha helices as red cylinders.121
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Figure 2-16. Multiple sequence alignment of SmTopoI_N65 and EcTopoIII.
Comparison of SmTopoI_N65, EcTopoIII (PDB 1D6M) via multiple sequence alignment
shows moderate sequence identity and similarity, with high sequence identity between
the highly conserved active sites. Identical residues are highlighted in red, similar
residues are highlighted in yellow, catalytic tyrosine is indicated with a red dot, active
site residues within 5 Å from catalytic tyrosine are indicated with blue dots, and the nineresidue loop extension seen in SmTopoI_N65 is indicated with a magenta bar.119,122
Reprinted from final submission with open access permission, Elsevier Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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more rigorous wash steps, and generally resulting in improved removal of non-specific
binding contaminant proteins, this concept was also explored by sub-cloning the target
gene from the pET15b vector into a pET16b vector, placing and extended deca-His tag at
the N-terminus.134,135 Finally, as the small ubiquitin-related modifier (SUMO) fusion
system has been reported to increase both target protein solubility and target protein
expression levels, the target was cloned into the pET SUMO vector system (SmTopASUMO) in order to analyze the usefulness of an N-term SUMO fusion protein along with
an N-term hexa-His tag.136,137
Of the various constructs examined, the product of the deca-his-tagged pET16b
construct (SmTopI16b) resulted in enough of an apparent increase in affinity for the
nickel column to be successfully exploited via a step-wise elution to satisfactorily isolate
the tagged target protein from the co-eluting contaminant proteins that plagued the hexahis-tagged pET15b construct. Furthermore, enzyme activity was maintained with the
deca-his-tagged construct, bypassing the immediate need for cleaving the affinity tag for
downstream applications—a luxury not necessarily expected with the larger SUMO
fusion tag construct (which also showed promising results in the purification trials).
Because the separation of DNA from DNA-binding proteins like topoisomerase I
is essential, yet particularly onerous, a protocol implementing a rapid and efficient means
of addressing this obstacle was highly desired. As an alternative to more traditional DNA
removal methods, the ionic strength of the buffers used in the IMAC purification step
were increased and the Ni2+-NTA-bound target protein was exposed to a high salt wash
over an extended period of time in order to successfully disrupt the largely electrostatic
nature of DNA-protein binding.138 Therefore, in order to further optimize SmTopI16b
yield, higher ionic strength buffers were employed to both increase the solubility of the
target protein as well as to aid in the expedited removal of DNA during purification steps.
Additionally, auto-induction was successfully adopted in order to increase yield and
greatly decrease the effort required during the expression and purification protocol. As
mini-expression analysis showed no apparent gain or loss in target solubility by adopting
auto-induction, it was deduced that the overall increase in target protein yield seen
between auto-induction and IPTG-induction likely resulted from greater overall growth.
Unique structural features of SmTopoI_N65
The SmTopoI_N65 model shows only 3 beta strands in D1, whereas EcTopoI and
MtTopoI each contain four D1 beta strands. Within 5 Å from the catalytic center of
Y316, only one dissimilar residue is observed between SmTopoI_N65 and
EcTopoI_N67, found between the two aspartates on the DXD TOPRIM motif—that is,
P101 on SmTopoI_N65, versus L112 on EcTopoI_N67. Interestingly, immediately prior
to the conserved active site, SmTopo_N65 displays a unique nine residue loop extension
(Figure 2-13 and Figure 2-14) not present in any of the topo I structures previously
determined, except for a similar but non-identical extension seen in topo I from the
extremophile Thermotoga maritima (PDB 2GAI; Figure 2-17). The SmTopoI_N65 loop
extension is mainly polar, with polar uncharged residues S307, N308, Q310, and Q311.
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Figure 2-17. Structural alignment of SmTopoI_N65 and TmTopoI (PDB 2GUI)
Structural alignment of SmTopoI_N65 (red) with topo I from the thermophile
Thermotoga maritima, TmTopoI (PDB 2GUI; green) shown in flat ribbon format
conducted with UCSF Chimera MatchMaker structure comparison tool.95,113 The unique
loop extension near the active site is highlighted with a red circle and the catalytic Y316
residue on SmTopoI_N65 if shown in stick format.
Reprinted from final submission with open access permission, Elsevier, Inc. ones, J. A. &
Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Further sequence alignment analysis of SmTopoI_N65 against several additional select
bacteria shows an intriguing lack of this nine-residue extension in several prominent gut
microbes, such as E. coli, Bacteroides ovatus, Bacteroides fragilis, and Bifidobacterium
breve, while a similar extension exists not only in the thermophile T. maritima, but also
in Staphylococcus aureus, Clostridioides difficile, and Neisseria gonorrhoeae (Figure
2-18). Lastly, as seen in MtTopoI, but dissimilar to EcTopoI_N67, SmTopoI_N65 lacks
an equivalent α1 helix in D4.
Summary
As a DNA binding enzyme, SmTopoI presents inherent difficulties during
expression and purification. Nonetheless, an effective, rapid, and simplified protocol was
developed for the high-yield expression and purification of bacterial topoisomerase I at
over 23 mg/L estimated at greater than 95% yield via SDS-PAGE analysis. With such a
substantial yield of active and highly pure full-length SmTopoI enzyme, the enzyme can
be used for effective biochemical and biophysical techniques that will allow for further
target characterization and validation studies, as well as future compound screening
campaigns and kinetic studies. Due to a number of circumstances, the full-length enzyme
is unfortunately not well-suited for a variety of structural studies. As the enzyme is
roughly 83 kDa, it is both too small for cryo-electron microscopy and too large for NMR.
Additionally, what is presumed to be the highly dynamic nature of the full-length enzyme
and the requisite high levels of salt necessary to maintain stability, it is also not wellsuited for X-ray crystallography.
Via rational construction of a shortened construct of SmTopoI, useful structural
information has nonetheless been attained from SmTopoI_N65 crystal structure
determination. Because of the inherently conserved nature of topo I, SmTopoI_N65
exhibits a substantial degree of sequence identity and similarity with other previously
determined topo I structures, including a highly conserved active site and similar overall
structure. Therefore, any novel distinction among topo I homologues is likely of
significant interest and, as such, the SmTopoI_N65 nine-residue extension located
immediately N-term-adjacent to the active site is notably unique as this extension is not
seen in topo I structures from either E. coli or M. tuberculosis. What may have gone
previously overlooked as an insignificant structural variation in topo I from an
extremophile inconsequential to human health (TmTopoI), the presence of this loop
extension in S. mutans—a bacterium noted for both its utility in research as a Grampositive model organism and its significance in dental and cardiovascular health—stands
as a structural dissimilarity that certainly draws attention and may warrant further
analysis. Its proximity to the enzyme active site is indeed intriguing, and important
questions regarding any underlying significance, including possible implications related
to enzymatic efficiency, target DNA sequence selectivity or stabilization, or even the
possibility of rationally designing selective catalytic topo I inhibitors that exploit partial
engagement with the extension, remain unanswered.
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Figure 2-18. SmTopoI_N65 multiple sequence alignment with select topo I
homologs of undetermined structure.
Comparison of SmTopoI_N65 with homologs from various select bacteria, including E.
coli, M. tuberculosis, T. maritima, S. aureus, C. difficile, N. gonorrhoeae, B. ovatus, B.
fragilis, and B. breve via multiple sequence alignment. Sequence alignment was
generated with the ESPript 3 server (http://espript.ibcp.fr/) using a multiple protein
sequence alignment produced with Clustal Omega, with secondary structure information
extracted from the SmTopoI_N65 structure.89,93,95,114,115 Alignment shows high degree of
sequence identity and similarity, including the highly conserved active site. Identical
residues are highlighted in red, similar residues are highlighted in yellow, catalytic
tyrosine is indicated with a red dot, active site residues within 5 Å from catalytic tyrosine
are indicated with blue dots, and the nine residue loop extension seen in SmTopoI_N65 is
indicated with a magenta bar.119,122
Reprinted from final submission with open access permission, Elsevier, Inc. Jones, J. A.
& Hevener, K. E. Crystal structure of the 65-kilodalton amino-terminal fragment of DNA
topoisomerase I from the gram-positive model organism Streptococcus mutans. Biochem
Biophys Res Commun, https://doi.org/10.1016/j.bbrc.2019.06.034 (2019. In Press).74
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Figure 2-18. Continued.
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Employing X-ray crystallographic methods, this work identified conditions
producing crystals that diffracted to 2.06 Å resolution, resulting in the first determined
topo I structure from a Gram-positive bacterium, SmTopoI_N65. This topo I fragment
structure offers important insight into both the similarities and differences between
bacterial topo I from several different relevant organisms. Continued efforts to
characterize SmTopoI are still warranted, including but not limited to the structural
determination of full-length SmTopoI, co-crystal structures with bound oligonucleotides,
enzymatic and kinetic studies, as well as various studies focused on the relatively unique
active-site-adjacent nine-residue loop extension highlighted in this work. Such studies
regarding the latter topic may include studies deleting, extending, or mutating the loop
itself, as well as side-by-side comparison of structural and enzymatic studies of topo I
enzymes from various bacterial organisms, including those with and without the loop
extension. Nonetheless, the results of these studies have improved our knowledge of topo
I and will facilitate future rational research efforts targeting this important enzyme.
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CHAPTER 3. TARGETING ACYL CARRIER PROTEIN (ACP)-ENOYL
REDUCTASE II (FABK): PRODUCTION, STABILIZATION, AND
CRYSTALLIZATION3
Introduction
Background
Clostridioides difficile (formerly Clostridium difficile) is a gram-positive, sporeforming, anaerobic pathogen that is the leading cause of health care-associated diarrhea
and gastroenteritis-associated deaths in the U.S.139-142 Clinical consequences of C.
difficile infection (CDI) range from asymptomatic or mild diarrhea to recalcitrant
diarrhea and fatal pseudomembranous colitis.143 CDI is caused by the eradication of key
gut flora, such as Bifidobacterium sp. and Bacteroides sp., which normally suppress C.
difficile overgrowth.144 This typically occurs via the use of broad-spectrum antibiotics
(e.g., clindamycin, fluoroquinolones, and beta-lactams).144-146 The first-line CDI
treatment, vancomycin, exhibits activity against beneficial gut flora and results in their
eradication, contributing to high rates of recurrence.147,148 Further contributing to relapse
is the pathogen’s ability to produce treatment-resistant spores that survive in the intestinal
tract.149,150 The emergence of epidemic strains, namely BI/NAP1/027 (North American
pulsed-field gel electrophoresis type 1, ribotype 027), correlated with an increase in
incidence and severity of CDI.147 While the alternative first-line drug fidaxomicin is
narrow-spectrum and reduces recurrence, it has failed to show evidence of doing so in
NAP1-mediated infections.151,152 Fecal microbiota transplantation (FMT) shows promise,
but long-term safety data is still lacking, including non-infectious microbiota-related
metabolic diseases like obesity.153,154 While new agents are currently in clinical trials,
recent failures highlight the pressing need for novel anti-CDI agents to maintain the
discovery pipeline.146,155 These issues emphasize that C. difficile remains a high-priority
candidate for the development of novel narrow-spectrum antibacterial agents.
Bacterial Type II Fatty Acid Biosynthesis (FAS II) Pathway
During cyclic fatty acid elongation within the bacterial type II fatty-acid synthesis
(FAS II) pathway, enoyl-acyl carrier protein (ACP) reductase enzymes catalyze the
critical, rate-limiting terminal reduction step. The FAS-II system provides fatty acid
precursory components vital to bacterial organisms for various biological processes like
membrane phospholipid production and sporulation.156 Strong scientific precedent
substantiates these enzymes as antimicrobial drug targets, exemplified by isoniazid, a
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Portions of chapter from final submission adapted with permission from Jones, J. A.* et al. Smallmolecule inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS Chem Biol,
https://doi.org/10.1021/acschembio.9b00293 (2019. In Press). (*Co-first author.) Copyright (2019)
American Chemical Society.139
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marketed inhibitor of tubercular InhA (enoyl-ACP reductase); triclosan, a well-known
antibacterial FabI inhibitor; and the anti-staphylococcal FabI inhibitor afabicin (Debio1450) currently in clinical trials.31,157-159 While the existence of four distinct enoyl
reductase isozymes (FabI, FabK, FabL, and FabV) in bacteria precludes the development
of broad-spectrum antibacterials targeting them, it affords an ideal opportunity for the
rational design of narrow-spectrum agents.68-70 Bioinformatics analyses of sequenced C.
difficile genomes indicate it expresses the FabK isozyme as its sole enoyl-ACP
reductase.67,160
FabK, a member of the triosephosphate isomerase (TIM) barrel family of
proteins, is a less abundant isozyme among the four enoyl-ACP reductases, and lacks
sequence similarity to FabI, FabL, and FabV, which are members of the short-chain
alcohol dehydrogenase/reductase (SDR) superfamily.69,161 Like the other isozymes, FabK
requires either NADH or NADPH as a cofactor for activity, but unlike its SDR
counterparts, FabK is a flavoenzyme that utilizes flavin mononucleotide (FMN) as an
active site prosthetic group. FabK is also unique in that it uses a bi-bi double
displacement (ping-pong) enzymatic mechanism for reducing its enoyl substrate.69,161-168
The SDR enzymes, however, possess a classical Rossman fold for binding their
NAD(P)H cofactor and rely on an ordered sequential enzyme mechanism for reducing
their enoyl substrates.169,170 While there has been recent debate about the essentiality of
the FAS-II pathway in Gram-positive bacteria,171-173 several groups have shown that
possession of the FapR regulatory system over FabT, as seen in S. aureus, prevents full
bypass of FAS-II inhibition by exogenous fatty acid uptake.71,72 Indeed, it was recently
showed that C. difficile, which also possesses FapR, behaves in a similar manner as
exogenous fatty acids were unable to rescue the pathogen from FAS-II inhibition.67 C.
difficile also has unique branched fatty acid requirements, further limiting the likelihood
of escape from FAS-II inhibition.174,175 Recent work also demonstrated the ability of
FAS-II inhibition to decrease spore formation by nearly 90%, which in principle could
reduce potential for spore survival, associated endogenous recurrence, and spore
dissemination.67
FabK as a Narrow-spectrum Target
CDI pharmacotherapy has shown that maximizing therapeutic success includes
preventing collateral damage to the GI microbiome. Important gut species such as Gramnegative Bacteroides sp.176 express FabI with or without FabK, while Bifidobacterium sp.
lack FabK entirely.67 Importantly, published FabK inhibitors are inactive against FabI
and FabI-bearing strains.164,167 Similarly, FabK has demonstrated resistance to FabI
inhibitors like triclosan, which are consequently inactive against strains carrying
FabK.69,162,177,178 Lastly, the ability of bacterial strains carrying two enoyl reductases to
survive the deletion of one isozyme suggests that both enzymes would need to be dually
inactivated to inhibit the growth of such organisms.68 This data justifies the investigation
of FabK as a narrow-spectrum target for selective anti-difficile therapy. In an effort to
initially characterize the enzyme target, the following research includes CdFabK
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expression and purification details, preliminary CdFabK characterization, and continuing
CdFabK protein crystallography work.
Aims
Protein Expression, Purification, and Stabilization of CdFabK
In order to carry out the desired enzyme target characterization and validation, a
high yield of high purity CdFabK was required. Because previous attempts had resulted
in low yields of inactive enzyme, a number of different purification methods were tested
to maximize the chances of success. As perhaps the most popular initial protein
purification is IMAC, this was attempted with various hexa-histidine tag placements,
including N-terminal and C-terminal tags. Additionally, native CdFabK was expressed
and purified as tag placement has been reported to impede both enzyme activity and
crystallization.179
While high quantity and purity of produced target enzyme is indeed of great
importance, the desire to develop assays for the screening of inhibitory compounds and to
characterize any potential compounds required the need for active and stable compounds.
As such, iterative and systematic trials were necessary for determining optimized storage,
assay, and crystallization conditions. Herein, the high-yield expression, rapid two-step
purification, and stable enzyme activity conditions of FabK from C.difficile is reported.
Production methods and can be carried out in a single day with an estimated purity of
95% or higher.
Crystallization of CdFabK
As the three-dimensional structure of CdFabK has not been previously
determined, a high resolution structure of CdFabK is required in order to conduct
structural characterization and structure-guided drug discovery efforts. As stated earlier,
the CdFabK enzyme is too small for cryo-EM studies and too large for NMR structural
studies. Therefore, X-ray crystallography is, by default, necessary for such requisite
structural determination and analyses. In order to crystallize CdFabK, a variety of coarse
crystallization screens for apo- and co-crystal CdFabK structures were carried out, and
subsequent fine screening trials were also conducted. Herein, the conditions for the
production of various moderate resolution CdFabK crystals is reported.
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Materials and Methods
CdFabK Construct Cloning, Plasmid Production, and Expression
The fabk gene from C. difficile strain 630 was commercially optimized,
synthesized, and cloned into the pET15b vector by GenScript (Piscataway, NJ) carrying
an N-terminal hexa-histidine tag.139 The gene was also cloned into the pET21d vector
with two different constructs, one carrying a C-term hexa-histidine tag, and the other
carrying no tag and encoding only the native enzyme as the gene of interest. The
respective plasmid products (CdFabK_15b, CdFabK_21d, and CdFabK_21d_NATIVE,
respectively) were then transformed into XL1-Blue Supercompetent cells (Agilent
Technologies, Santa Clara, CA) per protocol. Upon successful transformation, the
plasmids were then isolated with the QIAprep Spin Miniprep Kit via protocol and the
sequences were confirmed via the University of Tennessee Health Science Center
(UTHSC) Molecular Research Center (MRC) sequencing services (Memphis, TN). After
sequence confirmation, the plasmids were also transformed into BL21(DE3)-Gold
Competent cells (Agilent Technologies, Santa Clara, CA) via protocol.
The proteins were overexpressed in E. coli BL21(DE3)-Gold Competent cells
(Agilent Technologies, Santa Clara, CA) cultivated at 37°C in TB medium with 100
g/mL ampicillin by transferring 1% (v/v) overnight culture into fresh medium. Cells
were allowed to grow until they reached an OD600 of ~ 0.6 and the protein expression was
induced with 0.1 mM IPTG supplemented with 0.5 mM flavin mononucleotide (FMN).
Growth temperature was decreased to 18C and cells were allowed to grow further for 18
hours at 18C. After induction and growth, the cells were harvested by centrifugation at
18000 x g for 15 minutes. Pellets were stored at -80C until use.
CdFabK_15b and CdFabK_21d Purification
Pellets were resuspended in CFabK Buffer A (20 mM HEPES buffer pH 8.0 with
300 mM NH4Cl, 1 mM DTT, 18% glycerol, 10 g/mL benzamidine, and 10 mM
imidazole). Lysis components were then added, including 0.5 mg/mL lysozyme, 10
µg/mL DNaseI, 5 mM MgCl2, 0.5% Triton-X 100, 25 mM sucrose, and 1 Pierce®
EDTA-free Protease inhibitor tablet per 50 mL. Cells were lysed at 4°C with gentle
stirring, then sonicated at 50% amplitude on ice for eight minutes with eight seconds on
and 24 seconds off. Lysates were centrifuged at 39,000  g for 15 minutes and the
supernatants were filtered through a 0.22 polyethersulfone (PES) syringe filter (EMD
Millipore, Billerica, MA).
His-tagged proteins were purified via immobilized metal affinity chromatography
(IMAC) by loading the filtered lysate on a HisTrap HP column (GE Life Sciences) in
CdFabK Buffer A, washed over 20 column volumes with CdFabK Buffer A, and eluted
via linear gradient to 100% CdFabK Buffer B (CdFabK Buffer A with 500 mM
imidazole) over 20 column volumes. Peak eluted proteins were pooled and further
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purified by SEC on a HiLoad 26/600 Superdex 200 PG size exclusion column (GE
Healthcare Life Sciences, Pittsburgh, PA) in CdFabK SEC Buffer (50 mM HEPES pH
8.0, 300 mM NH4Cl, 18% glycerol, and 3 mM DTT) via isocratic elution. After
purification, proteins were concentrated via 10,000 MWCO Amicon™ Ultra-15
Centrifugal Filter Units and brought to 100 M with 38.5% glycerol, snap frozen in
liquid nitrogen, and stored at -80°C until future use. Proteins have been confirmed active
up to six months after storage under these conditions. Enzyme was confirmed via SDSPAGE gel analysis (Mini-PROTEAN® TGX Stain-Free™ Pre-Cast Gel and Precision
Plus Protein™ Unstained Standard, Bio-Rad Laboratories, Hercules, CA) and the enzyme
activity was analyzed in an Implen NP80 nanophotometer as described below (West Lake
Village, CA). Enzyme concentration was determined via PierceTM 660nm Protein Assay
Reagent (ThermoFisher Scientific, Waltham, MA) per protocol.
CdFabK_21d_NATIVE Purification
Pellets were resuspended in Anion Buffer A (20 mM BIS TRIS Propane buffer
pH 9.5, 1 mM DTT, and 18% glycerol). Lysis components were then added, including
0.5 mg/mL lysozyme, 10 µg/mL DNaseI, 0.5% Triton-X 100, and 1 Pierce® EDTA-free
Protease inhibitor tablet per 50 mL. Cells were lysed at 4°C with gentle stirring, then
sonicated at 50% amplitude for eight minutes with eight seconds on and 24 seconds off.
Lysates were centrifuged at 39,000  g for 15 minutes and the supernatants were filtered
through a 0.22 PES syringe filter (EMD Millipore, Billerica, MA).
Native CdFabK protein (CdFabK_NATIVE) was purified via anion exchange
chromatography by loading the filtered lysate on HiTrap Q HP GE Column (GE Life
Sciences) in Anion Buffer A, subsequently washed with 20 column volumes with Anion
Buffer A, and then eluted via linear gradient to 100% Anion Buffer B (Anion Buffer A
with 500 mM NH4Cl) over 20 column volumes. The 450 nm wavelength was followed to
discern fractions containing FabK cofactor, flavin mononucleotide (FMN), which was
followed to track the presence of the CdFabK_NATIVE protein. Fractions were collected
and pooled, enzyme was confirmed via PAGE gel analysis, and the enzyme activity was
analyzed in an Implen NP80 nanophotometer as described below (West Lake Village,
CA). Enzyme concentration was determined via PierceTM 660nm Protein Assay Reagent
(ThermoFisher Scientific (Waltham, MA, USA) per protocol.
CdFabK Activity and Stability Assays
Salt trials
All activity and stability assays were carried out at 25°C. Trials were conducted in
the presence of 50 nM CdFabK_15b N-term hexa-His tagged target enzyme, 5% DMSO,
150 M Cro-CoA, and 150 M NADH in an overall volume of 100 L in the following
various assay buffers: CdFabK Salt Assay Buffer 1 (HEPES pH 7.5, 0 mM NH4Cl, and
4% glycerol), CdFabK Salt Assay Buffer 2 (HEPES pH 7.5, 100 mM NH4Cl, and 4%
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glycerol), CdFabK Salt Assay Buffer 3 (HEPES pH 7.5, 300 mM NH4Cl, and 4%
glycerol), and CdFabK Salt Assay Buffer 4 (HEPES pH 7.5, 500 mM NH4Cl, and 4%
glycerol). DMSO and enzyme were incubated together for 5 minutes before the Cro-CoA
substrate was added and the reaction was started immediately afterward via the addition
of NADH. NADH absorbance (340 nm) was measured in a Biotek Synergy H1
microplate reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™
384-Well µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second
intervals for 7 minutes to evaluate the rate of reaction.
Glycerol trials
Trials were conducted in the presence of 50 nM CdFabK_15b N-term hexa-His
tagged target enzyme, 5% DMSO, 150 M Cro-CoA, and 150 M NADH in an overall
volume of 100 L in the following various assay buffers: CdFabK Glycerol Assay Buffer
1 (HEPES pH 7.5, 500 mM NH4Cl, and 0% glycerol), CdFabK Glycerol Assay Buffer 2
(HEPES pH 7.5, 500 mM NH4Cl, and 4% glycerol), CdFabK Glycerol Assay Buffer 3
(HEPES pH 7.5, 500 mM NH4Cl, and 10% glycerol), and CdFabK Glycerol Assay
Buffer 4 (HEPES pH 7.5, 500 mM NH4Cl, and 15% glycerol). DMSO and enzyme were
incubated together for 5 minutes before the Cro-CoA substrate was added and the
reaction was started immediately afterward via the addition of NADH. NADH
absorbance (340 nm) was measured in a Biotek Synergy H1 microplate reader
(Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™
Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 7 minutes to
evaluate the rate of reaction.
Buffer and pH trials
Trials were conducted in the presence of 50 nM CdFabK_15b N-term hexa-His
tagged target enzyme, 5% DMSO, 150 M Cro-CoA, and 150 M NADH in an overall
volume of 100 L in the following various assay buffers: CdFabK pH Assay Buffer 1
(100 mM MES pH 5.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer 2
(100 mM MES pH 6.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer 3
(100 mM HEPES pH 7.5, 500 mM NH4Cl, and 10% glycerol), CdFabK pH Assay Buffer
4 (100 mM HEPES pH 8.5, 500 mM NH4Cl, and 10% glycerol), and CdFabK pH Assay
Buffer 5 (100 mM CHES pH 9.5, 500 mM NH4Cl, and 10% glycerol). DMSO and
enzyme were incubated together for 5 minutes before the Cro-CoA substrate was added
and the reaction was started immediately afterward via the addition of NADH. NADH
absorbance (340 nm) was measured in a Biotek Synergy H1 microplate reader
(Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™
Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 7 minutes to
evaluate the rate of reaction.
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CdFabK Stability Trials
Initial -Globulins dilution assays
Stability assays were carried out at 25°C in the presence of 50 nM CdFabK_15b
N-term hexa-His tagged target enzyme, 10% DMSO, 150 M Cro-CoA, and 150 M
NADH in an overall volume of 100 L, in CdFabK Assay Buffer (HEPES pH 8.0, 500
mM NH4Cl, and 10% glycerol). The enzyme was diluted from the 100 M storage stock
concentration to 1 M working stock concentration in CdFabK Assay Buffer with
varying amounts of -Globulins (Sigma Aldrich, St. Louis, MO)—ranging from 0 mg/mL
(0 mg/mL overall assay concentration) to 2.5 mg/mL (0.125 mg/mL overall assay
concentration), and then allowed to incubate at 25°C for 0, 30, and 60 minutes. Enzyme
from each time point and -Globulin dilution concentration was then incubated with
DMSO as a positive control for 10 minutes before the Cro-CoA substrate was added and
the reaction was started immediately afterward via the addition of 50 L 300 M NADH.
NADH fluorescence (340 nm/460 nm) was measured in a Biotek Synergy H1 microplate
reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well
µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second intervals for 10
minutes to evaluate the rate of reaction.
Optimizing -Globulins dilution assays
Maximal CdFabK dilution assays were carried out at 25°C in the presence of twofold dilutions of 50 nM CdFabK_15b N-term hexa-His tagged target enzyme down to
6.25 nM CdFabK_15b. Assays were carried out in 10% DMSO, 300 M Cro-CoA, and
125 M NADH in an overall volume of 100 L, in CdFabK Assay Buffer (HEPES pH
8.0, 500 mM NH4Cl, and 10% glycerol). The enzyme was diluted from the 100 M
storage stock concentration to 1 M, 0.5 M, 0.25 M, and 0.125 M working stock
concentrations in CdFabK Assay Buffer with an increased 5 mg/mL -Globulins (0.25
mg/mL overall assay concentration), and then allowed to incubate at 25°C for 30
minutes. Enzyme was then incubated in assay buffer with DMSO as a positive control for
10 minutes before the Cro-CoA substrate was added and the reaction was started
immediately afterward via the addition of 50 L 250 M NADH. NADH fluorescence
(340 nm/460 nm) was measured in a Biotek Synergy H1 microplate reader (Winooski,
VT) in a final volume of 100 L in Greiner Bio-One™ 384-Well µClear™ Bottom
Polystyrene Microplates (Monroe, NC) via 15 second intervals for 30 minutes to evaluate
the rate of reaction and to monitor for any eventual loss of enzyme activity.
CdFabK Crystallization
CdFabK_21d crystals
C-term hexa-histidine tagged CdFabK_21d was crystallized at 5 mg mL-1 in a
3uL:3uL 1:1 ratio protein to condition using the hanging-drop vapor-diffusion method off
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of a coarse-matrix screen. The initial crystal growth condition was Morpheus (Molecular
Dimensions, Maumee, OH) condition 1-48 (0.12 M alcohols mix of 0.2 M 1,6hexanediol, 0.2 M 1-butanediol, 0.2 M 1,2-propanediol, 0.2 M 2-propanol, 0.2 M 1,4butanediol, and 0.2 M 1,3-propanediol; 0.1 M buffer mix of Tris base and BICINE, pH
8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25%
polyethylene glycol 1000, and 25% polyethylene glycol 3500) at 18°C. Crystals were
collected for X-ray diffraction analysis. Crystals were grown in 48-well VDX plates with
sealant (Hampton Research, Aliso Viejo, CA) and were visible within one week.
CdFabK_15b crystals
N-term hexa-histidine tagged CdFabK_15b was crystallized at 4.8 mg mL-1 in a
7uL:7uL 1:1 ratio protein to condition using the hanging-drop vapor-diffusion method off
of a coarse-matrix screen. The initial crystal growth condition was Morpheus (Molecular
Dimensions, Maumee, OH) condition 2-48 (0.1 M amino acids mix of 0.2 M DLglutamic acid monohydrate, 0.2 M DL-alanine, 0.2 M glycine, 0.2 M DL-lysine
monohydrochloride, and 0.2 M DL-serine; 0.1 M buffer mix of Tris base and BICINE,
pH 8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25%
polyethylene glycol 1000, and 25% polyethylene glycol 3500) at 18°C. Crystals were
collected for X-ray diffraction analysis. Optimized crystals were then obtained via cocrystallization in the same Morpheus 2-48 condition at 4.8 mg ml -1 in 7uL:7uL 1:1 ratio
of protein to a mix of 93% crystallization condition and 7% 10 mM phenylimidazole
compound 1g (see Chapter 4) in DMSO. Crystals were obtained using the hanging-drop
vapor-diffusion method. Crystals were grown in 48-well VDX plates with sealant
(Hampton Research, Aliso Viejo, CA) and were visible within five days.
Results
Cloning and Expression of Recombinant CdFabK
Substantial amounts of pure, active target CdFabK protein are needed for the
various characterization and validation studies required for effective CdFabK-directed
drug discovery and development efforts. Again, cloning into various histidine affinity tag
systems was chosen and implemented. For the sake of speed, the C. difficile fabK gene
was commercially optimized, cloned, and inserted into the pET15b vector
(CdFabK_15b), introducing the popular hexa-Histidine (hexa-His) tag at the N-terminus
of the target enzyme for effective first-round purification.123 For thorough analysis, the
target gene was previously cloned into several alternative vectors to study the effects of
affinity tag placement at either the amino or carboxy terminus, as well as native enzyme
without any tag. BL21(DE3)-Gold Competent cells were used for the over-expression of
target protein. Yellow pellets were noticed upon growth and expression of all three
constructs.
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Purification of Recombinant CdFabK Constructs
As a traditional first step purification method for many target enzymes, Ni2+-NTA
IMAC purification of CdFabK with the pET21d C-term hexa-His tag system and the
pET15b N-term hexa-His tag system both resulted in high yields (greater than 25 mg/L)
of initially active enzyme when high levels of glycerol, such as 18%, were used
throughout the purification steps. As the C-term hexa-His tagged enzyme (CdFabK_21d)
proved to lose activity rapidly, the N-term hexa-His tagged construct (CdFabK_15b)
became the construct of choice. Following successful IMAC purification, further
purification of CdFabK_15b was carried out via size exclusion chromatography and
resulted in highly pure enzyme of at least 95% purity via SDS-PAGE analysis (Figure
3-1) and high overall yields greater than 10 mg/L determined via 660nm protein
concentration assay with BSA as a standard. Target enzyme solubility was determined
satisfactory for immediate pooling and purifying via SEC without needing to buffer
exchange or dialyze, leading to a highly rapid and simple purification protocol that can be
conducted in one to two days. Under current storage conditions at -80°C (Materials and
Methods), enzyme has been determined active for over six months.
The native CdFabK target enzyme was also purified via preliminary anion
exchange chromatography, but the purity in comparison to the N-term hexa-His tagged
construct was quite poor and further protocol development for purifying the native target
enzyme was suspended for the time being.
Characterization of CdFabK
As the overall stability of CdFabK_21d had been determined previously to be
very poor, CdFabK_15b was expressed, purified, and tested for comparative stability. Via
systematic stability and activity trials, effective assay conditions were determined for
CdFabK_15b with a trend of relatively high NH4Cl, relatively high glycerol, and slightly
basic pH conditions combining for optimal conditions of HEPES pH 8.0, 500 mM
NH4Cl, and 10% glycerol (Figure 3-2). Even with the optimized assay conditions,
however, the target enzyme lost activity soon after being diluted to concentrations needed
for making a working enzyme stock solution for compound screening. The addition of
just 2.5 mg/mL -Globulins to the dilution buffer was determined to greatly increase the
duration of activity of the diluted enzyme at an overall concentration of 50 nM from just
a few minutes up to at least one hour (Figure 3-3). Additionally, increasing the Globulins even further to 5 mg/mL and doubling the substrate concentration to account
for extended assay duration to 300 M allowed for further dilutions of enzyme
concentration down to single-digit nanomolar (6.25 nM) with the capability of sustained
activity for at least 30 minutes (Figure 3-4).
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Figure 3-1.

SDS-PAGE gel of CdFabK_15b purification results.

(A) Stain-free SDS-PAGE. L, ladder; CE, clarified extract from IPTG-induction growth;
Ni2+, target fraction from nickel column; SE1, target fraction from beginning of size
exclusion peak; SE2, target fraction from middle of size exclusion peak.

Figure 3-2.

Enzyme activity studies of CdFabK_15b.

(A) CdFabK_15b stability trials measuring enzyme activity in different NH4Cl salt
concentrations, 0 mM (blue line with squares), 100 mM (green line with dots), 300 mM
(purple line with diamonds), and 500 mM (red line with squares). (B) CdFabK_15b
stability trials measuring enzyme activity in different glycerol concentrations, 0% (black
line with triangles), 4% (orange line with diamonds), 10% (red line with squares), and
15% (blue line with dots). (C) CdFabK_15b stability trials measuring enzyme activity in
different buffers and at different pH values, MES pH 5.5 (blue line with dots), MES pH
6.5 (red line with squares), HEPES pH 7.5 (green line with triangles), HEPES pH 8.0
(black line with dots), HEPES pH 8.5 (orange line with diamonds), and CHES pH 9.5
(purple line with upside down triangles). All reactions were carried out in the presence of
a fixed concentration of NADH (150 M) and Cro-CoA (150 M).
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Figure 3-3.

Enzyme dilution and stability studies of CdFabK_15b.

(A) CdFabK_15b stability trials measuring enzyme activity while diluted to 50 nM at
different incubation times 0 minutes (green line with circles), 30 minutes (red line with
squares), and 60 minutes (blue line with triangles). (B) CdFabK_15b stability trials
measuring enzyme activity while diluted to 50 nM at different incubation times 0 minutes
(green line with circles), 30 minutes (red line with squares), and 60 minutes (blue line
with triangles) after having been diluted into a working stock including 2.5 mg/mL of Globulins and an overall assay concentration of 0.125 mg/mL -Globulins. All reactions
were carried out in the presence of a fixed concentration of NADH (150 M) and CroCoA (150 M).
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Figure 3-4.

Extended enzyme dilution and stability studies of CdFabK_15b.

CdFabK_15b stability trials measuring enzyme activity at different two fold dilutions 50
nM (blue line with dots), 25 nM (red line with squares), 12.5 nM (green line with
triangles), and 6.25 nM (purple line with upside down triangles), and NADH control
without enzyme (orange line with diamonds) after thirty minutes of incubation and a
reaction runtime of thirty minutes. CdFabK_15b was diluted into a working stock
including 5 mg/mL of -Globulins and an overall assay concentration of 0.25 mg/mL Globulins. All reactions were carried out in the presence of a fixed concentration of
NADH (150 M) and Cro-CoA (300 M).
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Crystallization of CdFabK_21d and CdFabK_15b
Crystallization conditions were determined for both CdFabK_21d and
CdFabK_15b (Figure 3-5). Protein crystals of CdFabK_21d were discovered first and
diffracted to roughly 4 Å. CdFabK_15b crystallization conditions were also determined,
and moderately optimized (as discussed in Materials and Methods) with the resulting
crystals diffracting to roughly 3.5 Å.
Discussion
CdFabK Production
CdFabK was produced with two different hexa-Histidine tags, each to high
homogeneity and purity (greater than 95% via SDS-PAGE analysis) and over 10 mg per
liter of culture, however the C-term His-tagged construct proved highly unstable, despite
significant efforts to optimize storage and activity assay conditions (data now shown).
Therefore, the N-term His-tagged construct was expressed, purified via two-step
purification, and studied further. Upon systematic stability and activity trial analysis, the
salt, glycerol, and buffer and pH conditions were optimized for this specific construct as
discussed below. While stored at -80°C, the activity of the enzyme remains well past six
months, which is an important factor considering the desire to make large amounts of a
single batch of enzyme, store it, and use it in the future for reliable and uniform and
comparable high throughput compound screening.
CdFabK Stabilization
Upon systematic optimization of activity buffer conditions, optimal conditions
were found to be 100 mM HEPES pH 8.0, 500 mM NH4Cl, and 10% glycerol. This takes
into account many considerations as the eventual goal of CdFabK production includes
future assay development for compound screening and inhibitor studies. As such, certain
factors of concern include, of course, target enzyme stability and activity during both
benchtop experiments as well as after long-term storage.180 During analysis of the activity
of the CdFabK_15b enzyme under diluted conditions generally conducive to creating
working enzyme stock concentrations needed for compound screening, it was discovered
that any significant dilution of CdFabK_15b below ~100 M resulted in relatively rapid
inactivation. Thus the addition of inert proteins were analyzed and the addition of Globulins to the assay buffer for the dilution of the enzyme storage stock to an enzyme
working stock was determined to greatly increase the overall stability of the enzyme with
respect to the duration of activity. This allowed for substantial dilutions that would afford
the opportunity to conduct assays in the presence of reasonable concentrations of DMSO
and at low enough enzyme concentrations needed to screen inhibitors.
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Figure 3-5.

CdFabK crystals.

A. Original CdFabK_21d C-term hexa-His tagged crystals grown at 18°C from coarse
Morpheus screen, condition 1-48 (0.12 M alcohols mix of 0.2 M 1,6-hexanediol, 0.2 M 1butanediol, 0.2 M 1,2-propanediol, 0.2 M 2-propanol, 0.2 M 1,4-butanediol, and 0.2 M
1,3-propanediol; 0.1 M buffer mix of Tris base and BICINE, pH 8.5; and 37.5% v/v
precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25% polyethylene glycol 1000, and
25% polyethylene glycol 3500). B. Optimized CdFabK_15b crystal grown at 18°C from
coarse Morpheus screen, condition 2-48 (0.1 M amino acids mix of 0.2 M DL-glutamic
acid monohydrate, 0.2 M DL-alanine, 0.2 M glycine, 0.2 M DL-lysine
monohydrochloride, and 0.2 M DL-serine; 0.1 M buffer mix of Tris base and BICINE,
pH 8.5; and 37.5% v/v precipitant mix of 25% v/v 2-methyl-2,4-pentanediol, 25%
polyethylene glycol 1000, and 25% polyethylene glycol 3500) with 1:1 protein to 7% 10
mM phenylimidazole compound 1g (see Chapter 4) and DMSO in Morpheus
crystallization condition 2-48.
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CdFabK Crystallization
CdFabK required certain conditions for activity and stability, namely high salt, at
least 300 mM NH4Cl, and high glycerol, 18%, not traditionally conducive to
crystallization. As different methods were being considered for the optimization of
crystallization standards, coarse crystallization trials were nonetheless attempted in the
meantime. To some degree of surprise, crystallization conditions for both the C-term and
N-term His-tagged constructs were discovered, despite the high salt and high glycerol
storage buffer conditions. While certainly a noteworthy accomplishment, the crystals
continually resulted in lower, relatively weak diffraction (higher than 3.5 Å) and were
therefore of little use in structure-guided drug development efforts.
Fine screening crystallization attempts were made to the best of in-lab abilities,
but initial efforts to do so were met with difficulty. The crystallization conditions were
very complex, including combinations of multiple precipitants like MPD, PEG 1000, and
PEG 3350 for both CdFabK construct hit conditions, and different complex ligand
combinations that include a mix of six different alcohols for the initial C-term hit
condition, and a complex ligand mix of five different amino acids for the N-term hit
condition. Therefore, the realistic opportunity for fine screening was somewhat limited
from the beginning and did not yield further results. As the crystals found off of the
coarse screens were not shown to diffract near 2 Å, three-dimensional crystal structures
have not been determined. Instead, additional crystallization and crystal optimization
trials have continued.
Such trials have included apo- and co-crystallography efforts with CdFabK_15b
and analogues of a known phenylimidazole FabK inhibitor compound.163 Additionally,
CdFabK_15b has been screened against multiple other coarse crystal screens at various
temperatures. Also, protein to crystallization condition ratios have been altered, as have
drop sizes, and hanging vs. sitting drop methods have been employed. An Additive
Screen (Hampton Research, Aliso Viejo, CA) has also been attempted, and different cryo
conditions have been analyzed, including various PEG compounds, glycerol contents,
sugars, oils, and so on. Various post-crystallization techniques reported in the literature,
such as annealing and denaturing methods, have been extensively attempted as well.181
Thus far, diffraction has not improved, and further consideration is undergoing.
Though generally reported in the literature to have little effect on crystal structure
quality and resolution, another consideration has been that the His-tag may interfere with
tight crystal packing and resulting resolution.182 As such, attempts were made to cleave
the His-tag off of CdFabK_15b via thrombin cleavage, but enzyme activity was
completely lost and not recovered after doing so (data not shown). It is surmised that the
reason for this is the extensive degree of dilution for extended amounts of time required
for the thrombin cleavage reaction to occur. Additionally, preliminary attempts have been
made to purify native, untagged CdFabK for eventual crystallization trials but, similar to
overall CdFabK crystallization studies, progress is ongoing.
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Summary
Recent studies have shown that the fabk gene in C. difficile, which codes for the
CdFabK enzyme, is essential, even in the presence of exogenous fatty acids.67 This alone
supports CdFabK as a potentially promising novel antibacterial target. However, as those
studies also show that a known inhibitor of CdFabK inhibits the growth of C. difficile
without substantially inhibiting the growth of several selected representatives of the
human microbiome, the promise and potential of CdFabK as a narrow-spectrum
antibacterial target is also notably suggested.67 In order to further investigate CdFabK as
a narrow spectrum target for antibacterial drug discovery, it was immediately necessary
to produce pure, active, and stable target protein for further characterization and
validation.
CdFabK initially proved to be a relatively unstable enzyme in that traditional
purification buffers resulted in low-yield and inactive target protein. Via iterative trials,
substantial yields of highly pure and active CdFabK are now rapidly obtainable.
Moreover, conditions for reproducible and reliable assaying of the target enzyme have
been determined, including assay buffer conditions and long-term storage conditions.
While the activity of the enzyme can now be reliably measured at a satisfactory 50 nM
conentration, the potential for measuring even lower concentrations—potentially into low
double-digit nanomolar to single-digit nanomolar concentrations—appears possible. As
this would be necessary for the testing of any potent CdFabK inhibitors discovered or
developed, this is indeed a substantial and necessary achievement. Immediate future
research, therefore, should include compound screening against CdFabK, as well as
enzymology and characterization of known FabK inhibitors (discussed further in Chapter
4).
Aside from producing pure, stable, and active enzyme for future compound
screening, solving the three-dimensional CdFabK structure via X-ray crystallography is
extremely important for future structure-guided drug discovery efforts. Unfortunately, the
crystallography results reported herein did not include crystallization conditions or
crystals that yielded the resolution needed to determine the structure of CdFabK at atomic
or near-atomic resolution (near 2 Å or lower), which would be necessary to observe
structural characteristics in high detail and molecular interactions for potential ligands.
Accordingly, future research should include continued crystallography efforts, both
aimed at further optimizing diffraction of current crystals from known crystallization
conditions, as well as determining new crystallization conditions and potentially
constructing FabK mutants for additional crystallography studies (discussed further in
Chapter 5).
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CHAPTER 4.

CDFABK ENZYMOLOGY AND MODALITY OF INHIBITION4
Introduction

FabK from S. pneumoniae (SpFabK) was shown by Takahata et al. to be
specifically inhibited by a compound (AG-205) they found during a high throughput
screening campaign, which led to the development of the more potent phenylimidazolederived class of inhibitors via iterative medicinal chemistry modifications (e.g., replacing
the amide linker with urea functionality, exploring various substitutions at the solvent
exposed head region, un-fusing the benzimidazole and benzothiazole ring systems, and
evaluating various substitutions at the tail region).166,168,183-185 Despite substantial gains in
potency, further development was ceased, possibly due to the unfortunate fact that
Streptococci are able to bypass FAS-II inhibition as they carry the FabT regulatory
system.171 Because C. difficile harbors the FapR regulatory system, it presents an
opportunity to renew the development of phenylimidazole FabK inhibitors.186 In an effort
to characterize the enzyme target, essential kinetic evaluations of CdFabK, including
substrate and cofactor Km determinations, inhibition modality, and substrate inhibition
effects are herein performed. Data is also reported showing phenylimidazoles display
potent on-target biochemical activity against CdFabK (Table 4-1) and are amenable to
modifications that improve physiochemical properties (Figure 4-1) while maintaining
biochemical and anti-C. difficile activity.
As discussed above, the type II bacterial fatty acid synthesis pathway, FAS II,
provides important fatty acid precursors for membrane phospholipids essential to
bacterial cells and integral to sporulation. The FAS II pathway is distinctly separate from
the mammalian FAS I pathway, which is composed of a single, multifunctional synthase,
thus the FAS II enzymes represent novel and selective antibacterial targets that remain
relatively unexploited. The structure and function of the enzymes in the bacterial FAS II
pathway have been previously reviewed.169,187-189 As a metabolic pathway there is some
concern about the ability of bacteria to bypass FAS II inhibition using exogenous fatty
acids and this has been the subject of intense debate.171-173
Recent work, however, has demonstrated that certain bacteria, including S.
aureus, remain susceptible to FAS II inhibition even in the presence of exogenous fatty
acids due to differences in their regulation of genetic expression and feedback regulatory
systems.71,190 As a rate-limiting enzyme in the FAS-II pathway, FabI, enoyl-[acyl-carrier
protein (ACP)] reductase, represents a particularly attractive drug target and a number of
inhibitors of this enzyme have been characterized.30,31,177,191-199 Triclosan, a stereotypical
FabI inhibitor with a diphenyl ether scaffold, has been marketed for a number of years
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Table 4-1.
analogues.

Inhibitory activity of Enoyl-ACP isozymes by phenylimidazole

Compound
Triclosan
1a
1b
1c
1d
1e
1f
1g
1h
AG-205

CdFabK IC50 [95% CI];
% Inhibition at 10 M
>100 M
>10 M; 38.51%
3.31 M; 95% CI [2.68, 4.19]
>10 M; 49.86%
>10 M; 44.80%
2.86 M [2.02, 4.35]
4.63 M [3.12, 8.02]
7.35 M [5.35, 11.65]
>10 µM; 35.58%
4.15 M [3.324, 5.597]

SpFabK IC50 [95% CI]
>100 M
0.730 M [0.434, 1.456]
0.067 M [0.054, 0.084]
0.242 M [0.214, 0.274]
0.198 M [0.178, 0.222]
0.078 M [0.066, 0.093]
0.163 M [0.124, 0.214]
0.085 M [0.072, 0.101]
0.538 M [0.433, 0.675]
5.32 M [4.378, 6.809]

CI, Confidence Interval
Reprinted from final submission with permission from Jones, J. A.* et al. Small-molecule
inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS
Chem Biol, https://doi.org/10.1021/acschembio.9b00293 (2019. In Press). (*Co-first
author.) Copyright (2019) American Chemical Society.139

Figure 4-1.

Phenylimidazole analogues 1a-h.
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and is used in a variety of over-the-counter household products as a sterilizing agent,
however it has low utility for systemic use because of poor bioavailability.200,201
Aims
While the fabk gene has been well-validated as an essential gene in C. difficile
within the literature, the necessity to further validate the CdFabK enzyme as a druggable,
selective antibacterial target still exists.67 In an effort to do so, the following work details
essential kinetic evaluations of CdFabK, including substrate and cofactor Km
determinations; substrate inhibition effects; and inhibition studies, including modality
data of phenylimidazole compounds and preliminary inhibition data of novel
benzothiazole compounds against CdFabK.
Materials and Methods
CdFabK_15b Cloning, Expression, Purification
The N-term hexa-histidine tagged CdFabK enzyme, CdFabK_15b, was produced
and purified as detailed previously in Chapter 3 and used for all CdFabK enzymology,
kinetic, and inhibitor studies discussed in this chapter.
SpFabK Cloning and Plasmid Construction
The fabk gene from S. pneumo strain R6 was cloned and amplified using standard
PCR protocol and restriction enzyme techniques. Primers were designed around the NdeI
and BamHI restriction sites using the following primers:
SpFabKfwd: 5’-GGAGGCATATGAAAACGCGTATTAC-3’
SpFabKrev: 5’-AAGGATCCTTAGTCATTTCTTACAACTCC -3’
The target gene was cloned into the pET15b vector and transformed into BL21-Gold
(DE3) cells (Agilent Technologies, Santa Clara, CA). The protein was overexpressed in
E. coli BL21-Gold (DE3) cells via cultivation at 37°C in TB medium with 100 g/mL
ampicillin by first transferring 1% (v/v) overnight culture into fresh medium. Cells were
allowed to grow until OD600 of ~ 0.6 and the protein expression was induced with 0.1
mM IPTG. Cells were allowed to grow further for 18 hours at 18C and the cells were
harvested by centrifugation at 18000 x g for 15 minutes. After induction and growth, the
cells were harvested by centrifugation at 18000 x g for 15 minutes. Pellets were stored at
-80C until use.
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SpFabK_15b Purification
The cell pellet was resuspended in 50 mL SpFabK Lysis Buffer (CdFabK Buffer
A with 0.5 mg/mL lysozyme, 1mg/100mL DNase, 5 mM MgCl2, 0.5% Triton-X, and 1
Pierce EDTA-free Protease Inhibitor tablet per 50 mL) and lysed at 4°C with gentle
stirring, then sonicated on ice at 50% amplitude for eight minutes, with eight seconds on
and 24 seconds off. The cell lysates were centrifuged at 39000 x g for 15 min and the
supernatant was passed through a 0.22 µM PES syringe filter (EMD Millipore, Billerica,
MA). N-term hexa-histidine tagged SpFabK (SpFabK_15b) was purified via immobilized
metal affinity chromatography (IMAC) by loading the filtered lysate on a HisTrap HP
column (GE Life Sciences) in SpFabK Buffer A, washed over 20 column volumes with
SpFabK Buffer A, and eluted via linear gradient to 100% SpFabK Buffer B (SpFabK
Buffer A with 500 mM imidazole) over 20 column volumes. After IMAC purification,
fractions were pooled and further purified by size exclusion chromatography (SEC) on a
HiLoad 26/600 Superdex 200 PG size exclusion column (GE Healthcare Life Sciences,
Pittsburgh, PA) in SpFabK SEC Buffer (50 mM Tris pH 7.4, 100 mM NH4Cl, and 3 mM
DTT) via isocratic elution. The enzyme was confirmed via PAGE gel analysis and the
enzyme activity was analyzed in an Implen NP80 nanophotometer as described below
(West Lake Village, CA). The protein was concentrated to 75 µM with 35% overall
glycerol and stored at -80°C until use.
SaFabI_15b Expression
FabI from S. aureus cloned into the pET15b vector (SaFabI_15b) was
transformed into BL21-Gold (DE3) cells (Agilent Technologies, Santa Clara, CA)
previously (data not shown), and SaFabI_15b was produced in high yield and purity as
reported elsewhere in the literature with minor modifications.194 Briefly, SaFabI_15b was
overexpressed at 37°C in TB medium with 100 g/mL ampicillin by transferring 1%
(v/v) overnight culture into fresh medium. Cells were allowed to grow until they reached
an OD600 of ~ 0.6 and the protein expression was induced with 0.5 mM IPTG grown
further for 4 hours at 37°C. After induction and growth, the cells were harvested by
centrifugation at 18000 x g for 15 minutes. Pellets were stored at -80C until use.
SaFabI_15b Purification
The cell pellet was resuspended in 50 mL SaFabI Buffer A (500 mM Tris pH 8.0,
500 mM NaCl, and 10 mM imidazole) with 0.5 mg/mL lysozyme, 1mg/100mL DNase, 5
mM MgCl2, 0.5% Triton-X, and 1 Pierce EDTA-free Protease Inhibitor tablet per 50 mL,
and lysed at 4°C with gentle stirring, then sonicated on ice at 50% amplitude for eight
minutes, with eight seconds on and 24 seconds off. The cell lysate was centrifuged at
39000 x g for 15 minutes and the supernatant was passed through a 0.22 µM PES filter
(EMD Millipore, Billerica, MA). The target protein purification was performed by
affinity chromatography on HisTrap HP column (GE Lifesciences) with SaFabI Buffer A
as binding and wash buffer and SaFabI Buffer B (SaFabI Buffer A with 500 mM
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imidazole) as elution buffer. Elution peaks were pooled and buffer exchanged in a 10,000
MWCO AmiconTM Ultra-15 Centrifugal Filter Unit from EMD Millipore® (Billerica,
MA) into SaFabI Storage Buffer (50 mM MES pH 5.5, 100 mM NaCl, 100 mM EDTA).
SaFabI_15b was confirmed via PAGE gel analysis and the enzyme activity was
confirmed in an Implen NP80 nanophotometer as described below (West Lake Village,
CA).
FAS-II Biochemical Enzyme Assays
All compounds were dissolved in DMSO at concentrations of 10 mM, then
further diluted in pure DMSO to the required concentrations. Both CdFabK and SpFabK
assays were conducted via the following protocol: Reactions were carried out at 25C in
FabK Assay Buffer (100 mM HEPES pH 8.0, 500 mM NH4Cl, 10% glycerol, and 0.125
mg/mL -Globulins; 10% DMSO) with 150 M Cro-CoA and 150 M NADH.
Compounds were incubated in three-fold dilutions (ranging from 100 M to 5 nM for
CdFabK and 33 M to 1.7 nM for SpFabK) in the presence of 50 nM target enzyme.
Compounds and enzyme were incubated together for 10 minutes before the Cro-CoA
substrate was added and the reaction was started immediately afterward via the addition
of NADH. NADH fluorescence (340 nm/460 nm) was measured in a Biotek Synergy H1
microplate reader (Winooski, VT) in a final volume of 100 L in Greiner Bio-One™
384-Well µClear™ Bottom Polystyrene Microplates (Monroe, NC) via 20 second
intervals for 10 minutes to evaluate the rate of reaction.
SaFabI assays were conducted at 25 C in FabI Assay Buffer (50 mM MES pH
5.5, 150 mM NaCl, 10 mM EDTA, and 2% DMSO) with 300 M NADPH and 1 mM
Cro-CoA. Compounds were incubated at 10 M with 500 nM SaFabI for 20 minutes.
Reactions were started via the addition of NADPH. NADPH absorbance was measured
(340 nm) every 10 seconds for 10 minutes in a final volume of 100 L to evaluate the
rate of reaction.
FabK IC50 Calculations and Kinetics
Starting at three minutes, linear slopes were measured for three additional minutes
and used to determine the reaction rates. Measurements were conducted in duplicate and
IC50s were calculated via GraphPad Prism 7.0d (La Jolla, CA) using four-parameter
logistic (Hill) curve analysis using the equation Y = Bottom + (Top –
Bottom)/[1+10^((LogIC50 – X)*HillSlope)], where X is logarithm of dose and Y is
response. Kinetics with respect to cofactor and substrates were also assessed via
GraphPad Prism 7.0d comparing both standard Michaelis-Menten and substrate inhibition
models.
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FabI Activity
Starting at two minutes, linear slopes were measured for three minutes and used to
determine the reaction rates. Measurements were conducted in duplicate and percent
inhibitions were calculated against un-inhibited enzyme.
Generation of SpFabK and CdFabK Sequence Alignment
SpFabK and CdFabK alignment figure generated with ESPript 3 server
(http://espript.ibcp.fr) using multiple protein sequence alignment from Clustal Omega
and secondary structure information from SpFabK structure (PDB 2Z6I).119,122
Results
The CdFabK Enzyme Possesses Intrinsic NADH Oxidative Activity and Double
Substrate Inhibition
The CdFabK enzyme displayed NADH oxidative activity in the absence of enoyl
substrate (Figure 4-2). Apparent Km (Kmapp) values were determined via 1.5-fold serial
dilutions of the NADH cofactor while holding the enoyl substrate, crotonyl coenzyme A
(Cro-CoA), constant at 150 M; likewise, 1.5-fold serial dilutions of Cro-CoA were
tested while holding the NADH cofactor constant at 150 M; and an alternative enoyl
substrate, octenoyl coenzyme A (Oct-CoA), was tested similarly via 1.5-fold dilutions
while holding NADH constant at 150 M. Initially, Kmapp values were determined via
standard Michaelis-Menten non-linear regression fits. However, upon further analysis,
the data for cofactor and substrates all fit a substrate inhibition model (R2 = 0.9854;
0.7607; and 0.8479, respectively) better than the poorly fit standard Michaelis-Menten
models. As such, respective Kmapp values for NADH, Cro-CoA, and octenoyl coenzyme
A were determined to be 138.1 M, 327.0 M, and 420.8 M, as opposed to 23.0 M,
176.0 M, and 65.5 M observed with the standard Michaelis-Menten model,
respectively.
Phenylimidazole-Derived Compounds Selectively Inhibit the C. difficile FabK
Enzyme
Phenylimidazole compounds have been shown to inhibit SpFabK (PDB 2Z6J) and
lack inhibitory activity against FabI from E. coli.183,184 To evaluate activity against
CdFabK, phenylimidazole compounds were screened against purified enzyme to
determine percent inhibition at 10 M. Compounds yielding over 50% inhibition were
further screened to determine on-target 50% inhibitory concentrations (IC50). Compounds
were also screened at 10 M against purified FabI from Staphylococcus aureus (SaFabI)
to directly compare activity profiles.
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Figure 4-2.

Enzyme kinetics of CdFabK vs. velocity.

(A) Non-linear regression curve fit of velocity of CdFabK with varying concentrations of
NADH (1.5-fold dilutions from 350 M to 9.1 M) at a fixed concentration of Cro-CoA
(325 M) demonstrating NADH substrate inhibition. Standard Michaelis-Menten fit
(dashed blue line) and substrate inhibition line (solid black line with dots) shown for
comparison. (B) Non-linear regression curve fit of velocity of CdFabK with varying
concentrations of enoyl substrate Cro-CoA (1.5-fold dilutions from 4500 M to 78 M
and 0 M) at a fixed concentration of NADH (125 M) demonstrating Cro-CoA
substrate inhibition. (C) Non-linear regression curve fit of velocity of CdFabK with
varying concentrations of alternative enoyl substrate octenoyl-CoA (1.5-fold dilutions
from 2500 M to 43 M and 0 M) at a fixed concentration of NADH (125 M)
demonstrating octenoyl-CoA substrate inhibition.
Reprinted from final submission with permission from Jones, J. A.* et al. Small-molecule
inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS
Chem Biol, https://doi.org/10.1021/acschembio.9b00293. (2019. In Press). (*Co-first
author.) Copyright (2019) American Chemical Society.139
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We confirmed the phenylimidazole compounds inhibit CdFabK in a dosedependent manner. All compounds except 1a, 1c, 1d, and 1h showed greater than 50%
inhibition of CdFabK at 10 M. IC50s ranged from 7.35 M with 1g to 2.86 M with 1e,
with the series prototype, 1b, showing an IC50 of 3.31 M. Resulting Hill coefficients
from IC50 logistic curve fits for 1b, 1e, and 1g were 0.901 (95% Confidence Interval (CI)
= 0.761-1.064), 0.8594 (95% CI = 0.6449-1.134), and 1.014 (95% CI = 0.7417-1.365),
respectively. These values are not significantly different from unity (Hill slope of 1.000),
suggesting these compounds display normal inhibitory behavior and do not bind
cooperatively, aggregate, form micelles, or demonstrate problematic insolubility. It also
indicates the enzyme’s active sites function independently, despite CdFabK being a
functional dimer.163,202
All compounds showed IC50s against SpFabK in the sub-micromolar range, with
1b resulting in an IC50 of 67 nM, roughly 49-fold better as compared to CdFabK.
Likewise, 1e and 1g resulted in respective IC50s of 78 and 85 nM against SpFabK,
illustrating roughly 87- and 37-fold better respective IC50s as compared to CdFabK.
While activity of 1b against SpFabK was more potent than against CdFabK, it was still
roughly 30 times less potent against SpFabK in our hands than reported elsewhere.184 As
the monomer enzyme concentration used here (50 nM) was lower than that used in
previous reports (about 60 nM), the reason for this discrepancy is not readily apparent.
FabI was confirmed to be resistant to the phenylimidazole compounds as both 1b and
AG-205 showed little inhibitory effect against SaFabI with percent inhibition values well
below 50% (22.40 and 18.22%, respectively) at 10 M.
The target specificity profile of CdFabK was examined via activity in the
presence of triclosan—a well-known, potent, slow-binding inhibitor of the FabI
isozyme.203 To verify our own methods, triclosan was confirmed to be a potent inhibitor
of SaFabI, with nearly 90% inhibition at 10 M. Like SpFabK, CdFabK proved to be
resistant to triclosan at 100 M and IC50 values were not determined.
Phenylimidazole Compound 1b is Competitive for NADH and Uncompetitive for the
Enoyl Substrate Against CdFabK
To elucidate the modality of inhibition of the phenylimidazole compounds against
CdFabK, we analyzed the inhibitory activity of 1b against purified enzyme in the
presence of varying concentrations of NADH while holding Cro-CoA constant, and
likewise in the presence of varying concentrations of Cro-CoA while holding NADH
constant. Both non-linear fits and Lineweaver-Burk plots were analyzed. The best nonlinear fits for each substrate suggest that 1b acts as a competitive inhibitor of CdFabK
with respect to NADH (R2 = 0.91) and an uncompetitive inhibitor with respect to CroCoA (R2 = 0.90). The Lineweaver-Burk plots for each substrate corroborate these
findings (Figure 4-3).
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Figure 4-3.
CdFabK.

Characterization of inhibitory activity and mechanism of 1b against

(A) Sigmoidal plots demonstrating dose response curves for the inhibition of CdFabK by
two different phenylimidazole analogues, 1b (black line with dots) and 1g (blue line with
triangles). (B) Sigmoidal plots as dose response curves for the inhibition of CdFabK by
1b with different concentrations of Cro-CoA, 150 µM Cro-CoA (black line with dots)
and 325 µM Cro-CoA (red line with squares). (C) Lineweaver-Burk plot showing
competitive inhibition of CdFabK binding NADH by 1b. CdFabK was incubated with
varying concentrations of 1b and NADH at a fixed concentration of Cro-CoA (325 µM).
Concentrations of 1b were 33 µM (closed circle), 11 µM (square), 3.67 µM (triangle),
1.22 µM (upside-down triangle), 0.4 µM (diamond), and 0 µM (open circle). (D)
Lineweaver-Burk plot showing uncompetitive inhibition of CdFabK binding Cro-CoA by
1b. CdFabK was incubated with varying concentrations of 1b and Cro-CoA at a fixed
concentration of NADH (150 µM). Concentrations of 1b were 33 µM (closed circle), 11
µM (square), 3.67 µM (triangle), 1.22 µM (upside-down triangle), 0.4 µM (diamond),
and 0 µM (open circle).
Reprinted from final submission with permission from Jones, J. A.* et al. Small-molecule
inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS
Chem Biol, https://doi.org/10.1021/acschembio.9b00293. (2019, In Press). (*Co-first
author.) Copyright (2019) American Chemical Society.139
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Benzothiazole Compound KH-70 Potently Inhibits CdFabK
Benzothiazole compounds have also been shown to inhibit SpFabK.167
Considering the lack of a significant difference between the observable potencies of
phenylimidazoles and the prototype benzothiazole compound AG-205 against CdFabK,
benzothiazole analogues were further considered. A hit determined from a virtual
screening shape matching campaign conducted by the principal investigator of the
laboratory resulted in a benzothiazole analogue, KH-70, that was later screened under the
same optimized Km conditions as 1b (Materials and Methods). KH-70 proved to be the
most potent inhibitor of CdFabK to date, with an IC50 of 0.3545 M (95% CI 0.2509 to
0.4923) (Figure 4-4)
Discussion
We report here the kinetic evaluation of CdFabK, the biochemical activity of a
series of phenylimidazole analogues, and microbiological data suggesting these
compounds’ selective antibacterial activity against C. difficile over several other
prominent gut organisms. The compounds display promising, low micromolar CdFabK
inhibitory activity without significantly affecting the in vitro growth of important gut
organisms. CdFabK biochemical activity assays confirmed the inhibitory activity of all
phenylimidazole analogues against CdFabK, with several showing potent, low
micromolar activity. This data further demonstrates the enzyme’s druggability and the
potential of the phenylimidazole compounds as leads for developing a novel series of
narrow-spectrum anti-C. difficile drug candidates. As the imidazole and thiazole-urea
moieties in the first-generation inhibitor 1b were predicted in modeling studies to
establish three hydrogen bond interactions, and thus play a significant role in FabK
binding, initial structure activity relationship (SAR) and physicochemical exploration
during druggability validation was focused on the 4-bromo-phenyl region of the molecule
(Figure 4-1). The calculated solubility of 1b is poor (cLogP 4.56). Therefore, in this
work, a new expanded set of substituents with different lipophilic and electronic
properties in the tail region were tested to further probe existing SAR as well as enhance
solubility. Specifically, six new compounds 1c-1h, along with two known compounds 1ab, were evaluated and, while chemical modifications did not substantially increase
potency, IC50 values against CdFabK indicate inhibitory activity was not abolished
despite crucial solubility enhancement via modification at this region. This is illustrated
by comparing 1b (4-bromophenyl, cLogP 4.56 and IC50 3.31 M) and 1g (4cyanophenyl, significantly improved cLogP 3.15, similar IC50 7.35 M). Because the
target enzyme’s natural, in vivo function involves the binding of relatively lipophilic fatty
acid precursor substrates, this was a noteworthy discovery that will serve as an important
structural basis for future inhibitor design and synthesis. While 1e and 1f showed MIC
values similar in potency to 1b and 1g, increased cLogP values (4.6 and 4.8, respectively)
for both compounds preclude them from further assessment.
A high degree of primary sequence identity and active site similarity exists
between CdFabK and SpFabK (58% overall identity, 74% overall similarity, and 1% gaps
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Figure 4-4.
KH-70.

Structure and dose response curve against CdFabK for the novel hit

(A) Structure of benzothiazole hit KH-70. (B) Sigmoidal plot demonstrating dose
response curve for the inhibition of CdFabK by KH-70.
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with 2 missing loops on SpFabK, PDB 2Z6J100% and 91% active site identity within 3 Å
and 4Å from bound inhibitors, respectively; Figure 4-5). Despite this, the
phenylimidazole compounds showed greater activity against SpFabK than CdFabK (submicromolar vs. low micromolar, respectively). The compounds, along with triclosan,
were tested against both FabK and FabI to determine comparative FAS-II inhibition
profiles. The compounds potently inhibited FabK but lacked activity against FabI, while
triclosan potently inhibited FabI but lacked activity against FabK. The reason for the
potency disparity of phenylimidazoles against the two similar FabK enzymes is not
readily apparent. The mode of inhibition for the phenylimidazoles was reported to be
competitive inhibition of SpFabK binding NADH and uncompetitive of SpFabK binding
Cro-CoA,163 and confirmed here to be the same against CdFabK (Figure 4-2) and
therefore not the cause for potency dissimilarity. Evaluation at incorrect Kmapp values of
substrate and cofactor was another potential cause for dissimilar potencies, therefore a
substrate inhibition model was considered, increasing the Kmapp of Cro-CoA to 327 M,
up from 176 M seen with a standard Michaelis-Menten model. After re-testing 1b
against CdFabK with 325 M Cro-CoA, the IC50 dropped from 3.31 M to 1.27 M.
While this resulted in an IC50 closer to that observed against SpFabK, it still represents a
roughly 19-fold increase and, therefore, also fails to fully explain the discrepancy. A final
consideration is the possibility that the unique requirement of C. difficile for branched
chain fatty acids may impact the substrate requirements of CdFabK, making a branched
enoyl substrate more appropriate than Cro-CoA for compound screening, or even
introducing the possibility of additional medicinal chemistry modifications to be made to
the phenylimidazole compounds suited specifically to CdFabK.
Interestingly, a return to the benzothiazole scaffold of AG-205 resulted in the very
recent discovery of a related compound, KH-70, that has proven to be the most potent
CdFabK inhibitor to date. In comparison to the phenylimidazole analogues and AG-205,
KH-70 possesses a shortened linker group and a sulfone moiety, either of which may
help improve the observed potency (Figure 4-4). Further consideration of benzothiazole
scaffolds is certainly warranted, and further KH-70 hit characterization and validation are
ongoing. Without such studies, current rationale for the increased potency of KH-70
against CdFabK remains, to some extent, speculation. As such, necessary SAR studies
are a primary goal for the future of this project.
Summary
With the continued use of broad-spectrum antibiotics, the increasingly
diminishing spectrum of useful anti-CDI antibacterial agents, and the increased incidence
of new pathogenic strains, the need for novel antibacterial agents targeting C. difficile
continues to outpace their discovery. As demonstrated in these studies, a notably
attractive target for antibacterial development resides in the bacterial FAS II pathway,
which is structurally dissimilar from the mammalian fatty-acid synthesis (FAS I)
pathway.204 FAS II also contains a number of dissimilar, independent enzymes and
enzyme homologues collectively responsible for the synthesis of important bacterial fatty
acid precursors and, therefore, appears inherently well-suited for selective targeting.186,205
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Figure 4-5.

Sequence alignment comparing CdFabK and SpFabK.

Identical residues are highlighted in red, similar residues are highlighted in yellow, and
active site residues, within 4 Å from phenylimidazole binding site, are indicated with a
blue dot.119,122
Reprinted from final submission with permission from Jones, J. A.* et al. Small-molecule
inhibition of the C. difficile FAS-II enzyme, FabK, results in selective activity. ACS
Chem Biol, https://doi.org/10.1021/acschembio.9b00293. (2019. In Press). (*Co-first
author.) Copyright (2019) American Chemical Society.139
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Additionally, the pathway has now been well-validated as being essential in both Gramnegative bacteria and a number of Gram-positive bacteria, even in the presence of
exogenous fatty acids.
Via direct comparison here of the phenylimidazole compounds’ IC50 values
against different purified enoyl-ACP reductase enzymes from different organisms, the
selective druggability of CdFabK can be confirmed. Furthermore, analysis of in vitro
MIC values of phenylimidazole compounds against various key gut microbes elsewhere
in the literature has further illustrated this.67 As such, the selective inhibition of CdFabK
represents a particularly promising pathway for future narrow-spectrum anti-difficile
development. In vivo efficacy, toxicity, and dysbiosis studies in animal models of
phenylimidazoles and derivatives will be indispensable for continued development and,
therefore, are anticipated for future studies. Furthermore, as more information pertaining
to the human microbiome continues to surface, an ongoing analysis of the distribution of
current and novel FAS-II isozymes across the increasing number of known gut microbes
will be of critical importance. Such analyses will guide an evolving understanding of the
extent of antibacterial specificity and overall promise that targeting FabK truly offers.
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CHAPTER 5.

DISCUSSION AND CONCLUSION
General Overview

Though the skillset required to address modern rational antibacterial drug
development may be somewhat daunting at first glance, so is the rising threat of
antibacterial resistance. It seems only fitting, then, that as the threat of resistance rises, so
too must an equal measure of intellect and innovation to meet it. As even homologues of
the same enzyme from different bacterial species may possess vastly different
characteristics, there is no pre-determined roadmap for addressing the needs one may
encounter when investigating novel antibacterial targets. Therefore, a wide and thorough
understanding of the various methods and techniques needed for such endeavors is a
necessity. Similarly, while even the best equipped laboratories likely do not possess every
single piece of instrumentation available for drug discovery research, a wide knowledge
base, experience, and familiarity with various methods and techniques offers the
adaptability and expertise necessary to overcome even the most difficult projects. Indeed,
understanding the advantages and disadvantages of different techniques, the overlap, and
the subtle differences one may offer as opposed to another all combines to benefit the
researcher.
While certainly not completely exhaustive, an effective combination of methods
and techniques were used in this work to investigate narrow spectrum antibacterial drug
targets. As can be observed, all of this work builds upon itself. From rational target
identification, to target production and preliminary characterization, to compound
screening and hit selection, to target and hit validation and characterization, and finally to
lead development and optimization, the techniques employed in this work are
representative of the necessary methodology required for a rational and early pre-clinical
investigation of antibacterial drug targets. While the actual near-end stage of discovering
and developing validated hits is indeed exciting and stands out from the rest of the work,
it is the early, more tedious research that precedes those discoveries that serves as the
actual foundation for later breakthroughs. For example, the arduous, repetitive science
that led to the production of stabilized CdFabK enzyme and balanced assay conditions
was an absolute prerequisite for the subsequent phenylimidazole CdFabK inhibitor
validation and preliminary biochemical screening of virtual screening hits. A brief
synopsis illustrating these very points is discussed below.
Results and Discussion of Methods and Techniques Employed in This Work
Target Identification and Production
Embarking on the investigation of arguably any novel and rational antibacterial
drug target begins simply with a thorough analysis of the data at hand. Whether it is
genomic data, microbiological data, or a basic literature search, the investigation of
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rational antibacterial targets requires just what the name implies, “rationalization.” The
work conducted herein marked the beginning of two different projects previously
conceptualized by the principal investigator of the laboratory based off of rational
navigation of literature and genomic data.
As seen in Chapter 2, at the time of inception, the bacterial topoisomerase I
project was undertaken based on the data available at the time, which indicated that
streptococci possessed the gene responsible for topoisomerase I, topA, and lacked the
gene responsible for topoisomerase III, topB. After this work had commenced, however,
protein annotations had arisen that introduced at least some level of doubt in both
directions. As the lab in which this work was carried out does not conduct actual bacterial
genetics research, a substantial amount of bioinformatic analysis was invested into
ascertaining whether or not streptococci do in fact possess the topB gene and, in turn,
express topoisomerase III. This included genomic analyses, gene searches, protein
searches, various BLAST searches, and various literature searches. At the time this work
was written, this question still remained.
Significant preliminary work has been conducted in order to further characterize
and validate bacterial topoisomerase I, including the development of a simplified and
rapid protocol for the high-yield production of pure and active full-length topoisomerase I
from the gram-positive model organism, S. mutans. Different affinity, fusion, and
solubility tags were utilized, as well as different expression systems and purification
modalities. The effectiveness of the protocol results in substantial target production that
can later be used for further investigational studies and, therefore, still represents a
valuable contribution. Whether or not streptococci produce topoisomerase III, the ability
to effectively produce the bacterial topoisomerase I target in bulk amounts opens up a
variety of studies that can be carried out, including but not limited to bacterial
topoisomerase I enzymology, assay development, compound screening, and further
structural studies. As several other notable pathogens express topoisomerase I as their
sole type IA topoisomerase, high-yield production of target SmTopoI not only permits
the continued investigation of the respective enzyme, but also affords the opportunity to
further characterize and validate the target and potentially translate the findings to those
pathogens where it is more certain bacterial topoisomerase I will represent a narrowspectrum antibacterial drug target. Furthermore, as topoisomerases are traditionally such
effective chemotherapeutic targets, the option of pursuing bacterial topoisomerase I as a
broad-spectrum antibacterial drug target also still exists.
With respect to the FabK project, effective collaborations ensued that answered
genetic essentiality questions, highlighting the importance and benefit of such
partnerships.67 Nonetheless, thorough bioinformatic analyses were also conducted with
respect to the fabK gene and ongoing evaluations are being undertaken to survey the FAS
II-related proteome of not only pathogenic bacteria, but also that of the ever-expanding
bacteria that comprise the human microbiome.206-208 Such a continuous bioinformatic
analysis has allowed for an ongoing and contemporaneous survey of the bacterial battle
field, as it were, and in turn acts as a type of real-time reconnaissance of the effects FabK
inhibition might have as pre-clinical research continues to progress.
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CdFabK enzyme target production evolved substantially throughout this work.
Different affinity tag placements were combined with multiple purification techniques,
along with systematic stability and activity studies in order to determine optimal salt,
glycerol, and buffer and pH conditions. Ultimately, what was originally an inactive and
later a relatively unstable enzyme, can now be produced and stored long-term as active
enzyme.
Preliminary Target Characterization
Initial difficulty was met when attempting to produce and characterize SmTopoI.
As stated earlier, the DNA-binding nature of the target introduced foundational
difficulties with procuring stable enzyme. Stabilizing conditions were elucidated via
implementation of the thermal shift assay, which indicated high salt and acidic stabilizing
conditions for full-length SmTopoI. Simple target enzyme parameter analysis, coupled
with in silico homology modeling and extensive literature searches led to rational
shortened construct design that later resulted in highly diffracting SmTopoI_N65 protein
crystals.209
As mentioned above, CdFabK stability and activity was optimized via systematic
salt, glycerol, and buffer and pH trials utilizing biochemical assays. This eventually
permitted further target characterization that ultimately furnished effective assay
conditions for inhibitor screening. Additionally, optimization of CdFabK stability under
prolonged dilution and exposure to DMSO was of particular significance as many recent
studies have underscored the importance of screening under extended enzyme-compound
incubation times in order to discover slow-binding inhibitors.210-213
Compound Screening and Hit Selection
As previously discussed, an initial method for screening compounds is at times an
intellectual one, first involving a thorough literature review in order to survey the
chemical characteristics of any known potential inhibitors or chemical probes of interest.
With respect to bacterial topoisomerase I, there is still no clinically marketed catalytic
topoisomerase I inhibitor to date, nor is there a standard, specific bacterial topoisomerase
I catalytic inhibitor reported in the literature for laboratory use. Regarding FabK,
prototype phenylimidazole and benzothiazole compounds used in previous studies
throughout the literature were found upon prior literature searches conducted by the
principal investigator of the laboratory.163-166 These previously known SpFabK inhibitors
served as the launching point for preliminary hit screening against CdFabK at 10 M as
discussed earlier in this work. Moreover, these inhibitors and additional phenylimidazole
analogues were similarly screened and hits were considered to be any compound that
resulted in over 50% CdFabK inhibition at the pre-determined 10 M concentration
cutoff point.
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Target and Hit Validation and Characterization
From the attained SmTopoI_N65 crystals, the three-dimensional structure of
SmTopoI_N65 was determined to 2.06 Å resolution, and structural characterization was
able to be conducted. This in turn resulted in a number of findings that significantly
added to the overall structural understanding and characterization of SmTopoI. This
includes overall similarities and differences between SmTopoI and topoisomerase I
homologues from other bacteria. Of particular note, these structural studies revealed a
relatively unique active site-adjacent loop that may be worth assessing in greater detail in
the future.
A thorough assessment of those phenylimidazole analogues and benzothiazoles
that met the 50% CdFabK inhibition at 10 M hit identification threshold indeed led to
further hit validation and IC50 knowledge that can be used in later lead optimization and
structure-guided lead development. Furthermore, phenylimidazole inhibitor modality
studies further validated the phenylimidazoles as CdFabK inhibitors and led to further
inhibitor characterization. CdFabK enzymology studies led to apparent Km
determinations for the NADH cofactor and Cro-CoA enoyl substrate, which in turn led to
optimal balanced assay conditions. This will allow for more effective compound
screening in the future as it will increase the chances of discovering both competitive and
uncompetitive inhibitors. Additional hit characterization was carried out via selectivity
analysis, which confirmed selective inhibition of FabK over an alternative bacterial enoyl
reductase, FabI.
Lead Development
With respect to CdFabK inhibitors, the phenylimidazole analogue 1g showed
noteworthy merit as it displayed potency slightly lower yet very similar to the
phenylimidazole prototype 1b, but also showed increased solubility. Previous hit
characterization allowed for the direct comparison of the IC50 values of the benzothiazole
prototype, AG-205, against CdFabK and SpFabK. Such a comparison indeed had
interesting and noteworthy implications. Namely, the medicinal chemistry modifications
made to AG-205 to arrive at phenylimidazole 1b that led to substantially improved
inhibitory potency against SpFabK (low micromolar to low nanomolar, respectively)
does not appear to translate to increased potency against CdFabK.164,166 As such, a
rational return to the original AG-205 benzothiazole scaffold was undertaken for an SAR
reset to be conducted more thoroughly in the future for effective lead development. In the
meantime, the alternative benzothiazole compound KH-70 recently exhibited the highest
observed inhibitory potency against CdFabK at the time of this work, suggesting at least
some degree of merit in this lead development strategy.
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Future Directions
The research presented here showcases the investigation of two very different
narrow spectrum targets in antibacterial drug discovery. Both projects presented unique
obstacles and successes and, therefore, required the implementation of various subjective
techniques and methods. While various aspects of each project progressed to different
stages, work remains regarding both projects.
Bacterial Topoisomerase I Project
Genomic analysis of streptococci
The lingering uncertainty regarding whether or not streptococci possess the topB
gene, and therefore whether or not streptococci indeed fit the original narrow spectrum
hypothesis, represents a quandary that must be resolved. As such, determining whether or
not streptococci possesses the topB gene and, therefore, whether or not they express
topoisomerase III should be a top priority for future work. Further bioinformatic analyses
would offer more information, but certainty is likely to only be found in benchtop
bacterial genetic work. As such work is outside the scope of the principal investigator’s
laboratory as it equipped at this time, a gifted collaborator with expertise in bacterial
genetics and, possibly, a research emphasis on streptococci would be of significant worth
to the future progress of this project.
Full-length SmTopoI crystal structure
Useful insights were indeed gleaned from the determination of the threedimensional structure of the shortened 65-kDa amino terminal fragment of SmTopoI,
SmTopoI_N65. However, as SmTopoI_N65 lacks the entire carboxy terminal domain, a
full-length structure of SmTopoI would contribute substantial structural information that
could potentially in turn be leveraged into effective structure-guided drug development
efforts. As it was already exhaustively determined to be unlikely, or at the very least
exceptionally difficult, to obtain full-length apo SmTopoI crystals, it is likely that cocrystallography trials involving short oligonucleotide substrates with or without additive
compounds would be of immediate benefit with respect to this particular aim. As SAR
studies are an eventual long-term goal, this is a logical next step for this project.
SmTopoI mutational studies
Knowledge gleaned from the determination of the SmTopoI_N65 crystal structure
includes the relatively unique nine amino acid loop extension immediately adjacent to the
active site. As this feature has not been discussed or elucidated any further in the
literature, a deeper understanding may be warranted. In order to probe any significance of
the loop, mutational studies could be undertaken to delete the loop and compare mutant
SmTopoI to wild-type SmTopoI. Any changes in enzyme kinetics or nucleotide binding
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specificity would be a significant discovery and, whether any notable change occurred or
not, would further the understanding of the loop extension. Additionally, it may help
ascertain whether or not the loop would be worth targeting or engaging for any future
rational antibacterial drug discovery efforts.
High throughput topoisomerase I assay development
Currently, the only well-validated assay for measuring the activity of bacterial
topoisomerase I is an agarose gel-based DNA relaxation assay. This technique, while
effective, is extremely low-throughput and is not immediately digitized for consistent
comparisons. As such, an immediate need for successful antibacterial drug discovery
efforts directed at topoisomerase I includes the development of a high throughput assay.
This would allow for effective and efficient screening of large compound libraries as well
as efficient enzymatic studies. As bacterial topoisomerase I acts independently of ATP
and instead relies on the torsional strain of negatively supercoiled DNA, the only
measurable entity for assaying is the actual extent of DNA supercoiling itself, which
presents an inherently difficult task. Nonetheless, such a development would be a
revolutionary advancement with respect to targeting bacterial topoisomerase I and is
highly needed.
CdFabK Project
Crystallography
Though diffracting CdFabK protein crystals have been acquired, the optimal
crystals thus far have only diffracted to roughly 3.5 Å. In order to serve any real utility in
structure-guided drug discovery efforts, high quality crystals that diffract near 2.0 Å or
better are necessary to analyze atomic level interactions and peptide sidechains. To this
end, numerous crystallography methods have been attempted up to this point to no avail.
Countless alternative crystallization methods remain to be tried, though, ranging from
immediately accessible techniques to those that are more arduous and time consuming.
Methods that could be attempted immediately include but are not limited to cocrystallizing different additive screens, co-crystallization trials with newly found inhibitor
like KH-70, producing the target enzyme in alternative buffers, increased purification
steps to remove any remaining contaminant proteins that may be interfering with crystal
packing and quality, and various digestion methods.214
More time consuming and taxing methods should also be explored, include
various target enzyme mutational or deletional studies for the purpose of construct
optimization, including modifying solvent exposed hydrophobic or flexible peptide
regions that may result in non-specific aggregation and compromise ordered crystal
lattice formation and organization.215,216 To this end, the determination of the CdFabK
structure from the current best diffracting crystals may only result in the discernment of
overall structure, but it may also afford insight into the crystallographic unit cell and
crystal packing modalities, which may help drive the rationalization strategy behind any
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future mutational studies. While all of these options are worthwhile endeavors, for the
mere sake of expediting the process, co-crystallography with newly discovered potent
CdFabK inhibitors would likely be an ideal place to start the next phase of a
crystallization campaign.
Further hit validation and characterization
As the benzothiazole analogue KH-70 was an extremely recent hit, further hit
validation and characterization need to be conducted. Similarly, additional SAR studies
should be undertaken, focusing on benzothiazole analogue SAR by synthetic medicinal
chemistry, or SAR by commerce (see below).
Compound screening
The optimized CdFabK assay conditions should be leveraged as practicably and
aggressively as possible for the discovery of novel CdFabK inhibitors. Small in-house
libraries can be immediately screened. Likewise, virtual screening campaigns have
already commenced by others in the laboratory, and high-priority in silico hits can be
screened and verified in vitro and further validated. The utility of discovering inhibitors
with both novel and similar scaffolds would be substantial. Novel scaffolds would
introduce a new SAR opportunity and help further characterize the CdFabK target, and
analogues of known inhibitor scaffolds would further elucidate current SAR studies.
Related to known scaffolds, analogues of current inhibitors could be searched for online
as a time- and cost-effective means of conducting SAR by commerce, effectively
furthering iterative lead development and SAR expansion on the phenylimidazole and
benzothiazole compounds.217,218
Orthogonal high throughput assay development
The current CdFabK assay methods involve monitoring the fluorescence or
absorbance of NADH during the enzymatic reaction. As many small molecules found in
various compound screening libraries are in fact fluorescent or colored, substantial
amounts of false positives can arise when using fluorescent- or absorbance-based
assays.219 An orthogonal assay capable of counter-screening and further validating any
potential hits discovered upon initial fluorescence- or absorbance-based assays (or vice
versa) would be of substantial value. Any such assay should possess a number of ideal
characteristics. First, it should be orthogonal to fluorescence- and absorbance-based
assays, as discussed, such as a chemiluminescent assay. It should also be plate-based in
order to accommodate high throughput implementation. Additionally, the ability to be
run in low-volume would be beneficial as it would decrease resource consumption and
assist in the high throughput requirement. Low cost would be ideal, but not a necessity as
high throughput screens are generally accepted as rather costly endeavors. And lastly, the
assay should be capable of producing a significantly high screening window coefficient,
or Z’ factor, under moderate controls in order to reliably report any discovered hits at the
predetermined thresholds.220,221
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Conclusions
Despite the recent increase in the number of novel antibacterial agents in the
pipeline, there is still a noticeably small number of agents that possess novel mechanisms
of action, and an even more noticeable absence of small-molecule compounds directed at
novel targets. In fact, the only antibacterial agent currently in the pipeline that is directed
at a novel target is the anti-pseudomonal synthetic beta hairpin peptidomimetic known as
murepavadin (POL7080, Polyphor, Ltd.) currently in late stage (Phase III)
development.6,38 While absolutely a welcome contribution to the fight against
antimicrobial resistance, murepavadin does not meet the criteria of being a “small
molecule,” and instead falls into the category of novel biologic agents increasing in
popularity across most areas of drug discovery.222 Again, while any novel antibacterial
agent is desirable, including any biologic, the desirable benefits of small-molecule
antibacterial agents should not be overlooked. This is especially the case when
considering antibacterials. Due to their inherent purpose, antibacterial agents in particular
need to exhibit significant stability, cost-effectiveness, and ease of widespread
administration. Rationale for this is due in part to the necessity for antibacterial
stockpiling, dispersal in potentially harsh climates where many major infectious diseases
are focused, and the need for rapid response to outbreaks or bioterror events. In general,
biologics are more expensive than small-molecule drugs, less stable, more likely to cause
adverse immune responses, and more difficult to administer.223 These points, on top of
the aforementioned fact that there are currently no novel small-molecule antibacterial
agents with novel targets in the current antibacterial drug discovery pipeline, highlight
the continuing and apparent need that still exists to fill this void.
Obvious merit exists for the development of narrow-spectrum antibacterial agents,
and calls for such are only gaining momentum.2,54 As discussed throughout this work,
significant advantages are associated with narrow spectrum antibacterial agents—mainly
the counter to the disadvantages seen with broad-spectrum antibacterial agents. In
general, the major benefits of narrow-spectrum agents include an attenuation of microbial
selection for wide-spread multidrug resistance pertaining not only to the pathogens
necessitating pharmacotherapy, but also commensal bacteria capable of harboring and
spreading resistance mechanisms, as well as the related mitigation of collateral damage to
the human microbiome. Though narrow-spectrum antibacterial drug discovery appears to
hold great potential value, it is not without significant price. As showcased in this work, a
substantial amount of rationalization and investment—intellectual or otherwise—is
required in the pursuit of narrow-spectrum targets in antibacterial drug discovery. This
includes target identification and production, preliminary target characterization,
compound screening and hit selection, further target and hit validation and
characterization, iterative lead development, followed by continued narrow-spectrum
activity and dysbiosis analyses on top of all of that. While indeed difficult, different
research groups are coming up with innovative modalities of identifying and pursuing
narrow-spectrum targets. Modern methods include targeting enzymes that are unique and
essential to specific pathogens of interest (as seen in this work), pursuing bacteriocins and
synthetic peptides that only target particular pathogens and, interestingly, a return to the
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whole-cell phenotypic screening modalities reminiscent of those used throughout the
golden era of antibacterial drug discovery.2,38,54,67
After surveying the global issue of antibacterial resistance and the concerted
efforts being undertaken to combat it, it is clear that a multi-faceted approach is required
to effectively respond to this growing threat. As such, it would be inaccurate to argue that
the only answer to the issues currently presented lies in narrow-spectrum antibacterials.
Instead, it represents a single component of a plurality of different approaches needed. As
long as infectious disease diagnostics are not instantaneous, broad-spectrum antibacterial
agents will always be necessary for empiric therapy. In an ideal situation, after an
accurate diagnosis is made, antibacterial de-escalation could be implemented and a
patient could be transitioned to a narrow-spectrum antibacterial therapy, thereby
effectively treating an infection and mitigating both the damage done to the patient’s
microbiome, and mitigating the promotion of antibacterial drug resistance. For this ideal
situation to occur, however, substantial progress still needs to be made toward the
development of narrow-spectrum antibacterial agents, and such progress begins with
earnest investment in the investigation of narrow-spectrum targets in antibacterial drug
discovery. This work highlights such investment and, in turn, progress with respect to the
investigation of both bacterial topoisomerase I and bacterial enoyl-acyl carrier protein
(ACP) reductase II, or FabK, as narrow-spectrum targets in antibacterial drug discovery.
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